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Abstract 
 
CRISPR (clustered regularly interspaced short palindromic repeat)-Cas 
(CRISPR-associated protein) systems are microbial adaptive immune systems against 
invading foreign genetic elements accompanying with viral infections and plasmids 
transfers. Cas proteins form effector ribonucleoprotein complexes with guide RNA, 
and the effector complexes recognize and degrade the target nucleic acids 
complementary to the guide sequences. CRISPR-Cas systems are divided into class 1 
and class 2. Class 2 CRISPR-Cas systems use a single Cas endonuclease as an effector 
element, and they are further divided into type II, V, and VI. Cas9, an effector protein 
of class 2 type II CRISPR-Cas system has been harnessed for gene editing tools. Cpf1 
(Cas12a) is an effector endonuclease of class 2 type V CRISPR-Cas systems. Cpf1s 
derived from Acidaminoncoccus sp. BV3L6 (AsCpf1) and Lachnospiraceae bacterium 
ND2006 (LbCpf1) exhibit robust DNA targeting and cleavage activities in eukaryotic 
cells, so they also have been harnessed for gene editing tools. 
Cpf1 shows some unique features different from Cas9 in the aspects of the target DNA 
cleavage and the PAM recognition. Therefore, it was predicted that the target DNA 
recognition and cleavage mechanisms of Cpf1 are different from Cas9. There was no 
structural information of Cpf1, so the reasons why Cpf1 exhibits such unique features 
remained elusive. Here in this study, we determined the crystal structures of Cpf1–
crRNA–target DNA complexes, and succeeded in revealed the working mechanisms of 
Cpf1. 
 
Crystal structure of Cpf1 in complex with guide RNA and target DNA 
Although the RuvC nuclease domain was predicted from the amino acids sequences of 
Cpf1, no other known domain structures were predicted. To reveal the working 
mechanisms of Cpf1, we determined the crystal structure of AsCpf1–crRNA–target 
DNA complex in 2.8 Å resolution. AsCpf1 adopts a bilobed architecture, and the 
RNA–DNA heteroduplex bound in the central channel. The TTTV PAM recognition 
mechanism of AsCpf1 was unveiled from this structure. AsCpf1 recognizes the shape 
of the PAM duplex and the bases of PAM nucleotides, which are referred to as shape 
readout and base readout respectively. Moreover, the mutation analysis and the target 
DNA cleavage assays revealed the target DNA cleavage mechanism. The results of 
assays indicated that both strands of the target DNA are cleaved by the RuvC domain, 
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and the Nuc domain guides the target DNA strand to the catalytic center of the RuvC 
domain. 
 
Structural basis for the altered PAM recognition by engineered 
CRISPR-Cpf1 
Cpf1–crRNA complex requires the TTTV PAM for target recognition. When Cpf1 is 
used for gene editing tools, the requirement of the TTTV PAM may limit the 
availability of the suitable target sites. To address this limitation, two AsCpf1 variants 
(RVR and RR) which recognize alternative PAMs are created by a structure-guided 
mutation screen. The RVR and RR variants recognize the TATV and TYCV PAMs 
respectively. However, how the Cpf1 variants recognize the altered PAM remains 
unknown. We determined the crystal structures of the RVR and RR variants in 
complex with crRNA and target DNA in 2.0 Å resolution. The new interactions were 
formed mainly between the altered PAM complementary nucleotides and the 
substituted residues. These high-resolution structures revealed the altered PAM 
recognition mechanisms and the roles of the substitutions of the Cpf1 variants. 
 
Structural basis for the canonical and non-canonical PAM recognition 
by CRISPR-Cpf1 
Recently PAM preferences of Cpf1s have been revealed. LbCpf1 and AsCpf1 prefer 
the canonical TTTV PAM. In addition, they also recognize non-canonical C-containing 
PAMs. To elucidate the non-canonical PAM recognition mechanisms of Cpf1, we 
determined the crystal structures of LbCpf1 in complex with crRNA and target DNA 
containing either TTTA, TCTA, TCCA, or CCCA as the PAM in 2.4–2.5 Å resolution. 
The canonical PAM recognition mechanism of LbCpf1 are similar to that of AsCpf1, 
and the PAM duplex in the TTTA PAM complex is highly distorted. In the 
C-containing PAM complex structures, the C-containing PAM duplexes adopt less 
distorted conformations compared to that of the TTTA complex. A structural 
comparison between the four complexes revealed altered hydrogen-bonding 
interactions between the PI domains and the PAM nucleotides, accompanying the 
displacement of their PI domains. These structures revealed the importance of the 
flexibility of the PI domains and the interactions between the PI domains and the PAM 
duplexes for the distinct PAM recognitions. 
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Table of abbreviations 
 
 
  
Abbreviation Full name 
DNA deoxyribonucleic acid 
RNA ribonucleic acid 
ss single-stranded 
ds double-stranded 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
kDa kilodalton 
IPTG isopropyl β-D-thiogalactopyranoside 
LB Luria-Bertani 
Ni-NTA nickel-nitrilotriacetic acid 
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PDB Protein Data Bank 
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TEV tobacco etch virus 
Tris tris(hydroxymethyl)aminomethane 
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Table of amino acid and nucleic acid base abbreviations 
Abbreviation Full name 
A, Ala alanine 
C, Cys cysteine 
D, Asp aspartic acid 
E, Glu glutamic acid 
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K, Lys lysine 
L, Leu leucine 
M, Met methionine 
N, Asn asparagine 
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S, Ser serine 
T, Thr threonine 
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T thymine 
G guanine 
C cytosine 
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Chapter 1: General introduction 
 
1.1 Overview of CRISPR-Cas systems 
Prokaryotes are constantly threatened by phage infection and invasion by mobile 
genetic elements through conjugation and transformation. CRISPR-Cas (clustered 
regularly interspaced short palindromic repeats and CRISPR associated) systems 
provide adaptive immunity for bacteria and archaea against foreign genetic elements 
(Doudna and Charpentier, 2014; Marraffini, 2015; Mohanraju et al., 2016; Wright et 
al., 2016) (Figure 1-1). A CRISPR locus is composed of CRISPR arrays and cas genes. 
CRISPR arrays contain variable spacer regions and conserved repeat regions, and cas 
genes are organized in operons. This system is conserved in about 50% of bacteria and 
almost all archaea (Sorek et al., 2013). Spacer sequences often match fragments of 
previously encountered foreign genetic elements, and they play a key role in memories 
of the invasions. Cas proteins, translated from the cas operons, and crRNAs (CRISPR 
RNAs), transcribed from the CRISPR array, play critical roles for the eliminations of 
the invading foreign genetic elements.  
 
The working mechanism of CRISPR-Cas system is constituted with three steps, 
“adaptation”, “expression”, and “interference”. In the first “adaptation” stage, invading 
foreign genetic elements were processed into short fragments and integrated into 
CRISPR arrays as new spacer sequences by the integration activity of the Cas1–Cas2 
hetero hexamer (Heler et al., 2015; Nuñez et al., 2014, 2015a, 2015b; Wang et al., 
2015; Wei et al., 2015; Wright et al., 2017; Xiao et al., 2017). In the second 
“expression” stage, crRNA precursors are transcribed from the CRISPR array, and 
mature crRNAs containing one repeat region and one spacer region are processed from 
the precursors. The mature crRNAs form effector complexes with effector proteins 
translated from cas operons. In the third “interference” stage, when foreign genetic 
elements with the same sequences invade again, the effector complexes recognize and 
degrade them by the sequence complementarity. 
 
For gene targeting by effector complexes, a PAM (protospacer adjacent motif), a short 
specific sequence, should exist at the proximal region of the target site, in addition to 
the sequence complementarity between the guide RNA and target DNA. A PAM plays 
an important role for the effector nucleases to distinguish the self-CRISPR array and 
non-self invading sequences (Deveau et al., 2008; Marraffini and Sontheimer, 2010; 
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Mojica et al., 2009; Sashital et al., 2012; Westra et al., 2013). These mechanisms are 
conserved features in all CRISPR-Cas systems.  
 
 
1.2 Discovery of CRISPR-Cas system 
In 1987, Japanese research group discovered characteristic roughly palindromic 
repeated sequences in Escherichia coli when they sequenced the iap gene (Ishino et al., 
1987). However, at that time, the functions of this repeat cluster were unknown. In 
2002, it is discovered that CRISPR arrays exist nearby some conserved genes, and 
short non-coding RNAs are transcribed from this repeat cluster (Tang et al., 2002). 
Arrays of these repeated sequences and associating genes were named as CRISPR and 
cas genes respectively (Jansen et al., 2002). As a result of accumulation of prokaryotic 
genome information, bio-informatic sequence analysis revealed the sequence 
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similarities between the spacer sequences and mobile genetic elements of phages and 
plasmids. This result suggested that the CRISPR array work as memories of invasion 
by foreign genetic elements (Mojica et al., 2005). 
In 2007, this hypothesis was proofed experimentally. A research group in Danisco, a 
bio-based company, investigated the genome of the phage resistant Streptococcus 
thermophiles, and found that the CRISPR array of S. thermophiles contain the same 
sequences to the phage genome, thereby elucidating the role and the importance of the 
spacer sequences in the adaptive immune system (Barrangou et al., 2007). Moreover, 
in 2008, some basal key features of CRISPR-Cas systems are characterized. First, Cas 
proteins form ribonucleoproteins with the short non-cording RNA (crRNA) transcribed 
from the CRISPR array, and Cas proteins are active in the complexes. Second, most of 
the effector complexes target the dsDNA derived from phages and plasmids. Third, the 
selections of the target sites mainly depend on the guide sequences of crRNA, 
therefore the effector complexes are programmable DNA endonucleases (Brouns et al., 
2008; Marraffini and Sontheimer, 2008). 
 
CRISPR-Cas systems are divided into class 1 and class 2 based on the construction of 
the effector complexes (Makarova et al., 2015; Nishimasu and Nureki, 2017; Shmakov 
et al., 2017). In class 1 CRISPR-Cas systems, Cas proteins form multi-subunit complex, 
and it form an effector complex with a crRNA (Figure 1-2). Class 1 CRISPR-Cas 
systems are further divided into type I, III and IV. The effector complex of class 1 type 
I CRISPR-Cas system is Cascade (CRISPR-associated complex for antiviral defence), 
and it is studied very well biochemically and structurally (Jackson et al., 2014; Jore et 
al., 2011; Mulepati et al., 2014; Wiedenheft et al., 2011; Zhao et al., 2014) (Figures 
1-2A and 1-2B). The effector complexes of class 1 type III CRISPR-Cas system are 
named as Cmr and Csm complex (Figures 1-2C and 1-2D). These complexes can target 
both DNA and RNA (Jiang et al., 2016b; Osawa et al., 2015; Samai et al., 2015; Taylor 
et al., 2015). In contrast, class 2 CRISPR-Cas systems, a single endonuclease form a 
ribonucleoprotein complex with crRNA and works as an effector complex. Cas9 is the 
most well characterized effector protein in class 2 type II CRISPR-Cas system (Figure 
1-3). In recent years, novel CRISPR-Cas systems are discovered one after another. In 
class 2 type V CRISPR-Cas system, Cpf1 (Cas12a) and C2c1 (Cas12b) are identified 
as effector proteins (Shmakov et al., 2015; Zetsche et al., 2015a). Whereas they target 
dsDNA, they exhibit some differences compared to Cas9. In class 2 type VI 
CRISPR-Cas system, C2c2 (Cas13a) is the effector protein, and this is the single 
protein which target ssRNA (Abudayyeh et al., 2016; East-Seletsky et al., 2016; Knott 
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et al., 2017; Liu et al., 2017a, 2017b). 
 
 
1.3 Cas9 
Cas9 is an effector endonuclease classified into the class 2 type II CRISPR-Cas system 
(Figures 1-3A and 1-3B). Cas9 has two nuclease domains, the RuvC and HNH domain 
(Barrangou et al., 2007), targets dsDNA, and creates a blunt end in the PAM proximal 
region (Garneau et al., 2010). In CRISPR-Cas systems, many effector proteins are 
single RNA-guided DNA endonucleases, cooperating with crRNAs. However, in 2011, 
the additional guide RNA of Cas9 was discovered in the CRISPR locus of 
Streptococcus pyogenes. The second guide RNA was necessary for the nuclease 
activity of Cas9, and it was named as tracrRNA (trans-activating crRNA) (Deltcheva et 
al., 2011) (Figure 1-3C). This discovery revealed that Cas9 is a dual RNA-guided 
DNA endonuclease, cooperating with crRNA and tracrRNA. SpCas9 (Streptococcus 
pyogenes Cas9) was characterized in 2012. The HNH and RuvC domains cleave the 
target DNA strand and non-target DNA strand, respectively. SpCas9 recognizes NGG 
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PAM (N is A, T, G or C). Cas9 is active with sgRNA (single-guide RNA) which is 
created by connecting crRNA and tracrRNA with an artificial linker loop (Jinek et al., 
2012). This character highlights the potential to exploit the system for programmable 
gene editing.  
 
To elucidate the unique working mechanisms of Cas9, structural information of Cas9 
is indispensable. The structures of SpCas9 in six different states have been reported 
(Apo-SpCas9, SpCas9–sgRNA binary complex, SpCas9–sgRNA–ssDNA ternary 
complex, and SpCas9–sgRNA–dsDNA complex) (Anders et al., 2014; Huai et al., 
2017; Jiang et al., 2015, 2016a; Jinek et al., 2014; Nishimasu et al., 2014) (Figure 
1-3D–1-3I). Cas9 is a bilobed structure constructed with the REC lobe and the NUC 
lobe. The REC lobe is constituted by the bridge helix (BH), the Rec1, Rec2 and Rec3 
domains, and the NUC lobe is constituted by the WED, PI, RuvC and HNH domains, 
respectively. The guide region of sgRNA and the target DNA form the RNA–DNA 
hetero duplex, and it is accommodated in the central channel between the two lobes. 
Based on these structures, the sgRNA, target DNA, and NGG PAM recognition 
mechanisms are revealed. Furthermore, the structural comparisons suggest the 
conformational changes of Cas9 accompanying with binding the sgRNA and the target 
DNA. The conformational changes of Cas9 were elucidated by FRET and AFM 
(Shibata et al., 2017; Sternberg et al., 2015). 
 
According to specific combinations of cas genes, class 2 type II systems are divided 
into three subtypes, type II-A, II-B, and II-C. The crystal structures of SpCas9 and 
SaCas9 (Staphylococcus aureus Cas9) in type II-A, FnCas9 (Francisella novicida 
Cas9) in type II-B, and CjCas9 (Campylobacter jejuni Cas9) in type II-C are 
determined (Hirano et al., 2016a; Nishimasu et al., 2015; Yamada et al., 2017). These 
structures were determined in complex with sgRNA and target DNA containing PAMs. 
The structural comparisons revealed the structural diversities and functional 
similarities of Cas9. Whereas there are no similarities in the amino acid sequences and 
structures of sgRNA, they are commonly bilobed structures and the hetero duplexes 
are accommodated in the central channels. In their working mechanisms, the 
requirement of PAM for dsDNA targeting and the target DNA cleavage mechanisms 
are conserved among the Cas9 family members.  
 
1.4 Application of Cas9 for gene editing tools  
The effector complexes of CRISPR-Cas systems are programmable endonucleases, 
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therefore they were expected to being applied for gene targeting tools (Marrafini et al., 
2008). Notably gene editing by Cas9 was demonstrated in vitro in 2012 and in vivo in 
2013 for the first time (Cong et al., 2013; Gasiunas et al., 2012; Jinek et al., 2012, 
2013; Hwang et al., 2013; Jiang et al., 2013; Mali et al., 2013). The target sites of Cas9 
are changed easily by changing the guide sequence of sgRNA. When the cleavage site 
is repaired, insertions and deletions are induced mistakenly. This is the core 
mechanism of gene editing, and it is applied for the knock down of the target gene and 
the knock in of specific sequences. Cas9 is a more advanced, inexpensive and easier 
genome editing tool compared to ZFNs (zinc finger nucleases) (Urnov et al., 2010) and 
TALENs (transcription activator-like effector nucleases) (Joung and Sander, 2013), 
making the gene editing technology more familiar for all scientists. This is the 
revolution in the field of life sciences and medical sciences. 
 
The gene editing technologies relating to Cas9 have improved rapidly (Barrangou and 
Doudna, 2016; Komor et al., 2016a). Whereas the guide sequences of sgRNAs are 
changed flexibly, the PAM should exist next to the target sites. It limits the selectivity 
of the target sites. To address this problem, Cas9 variants with altered PAM 
specificities are created. Originally WT SpCas9 recognizes NGG PAM and WT 
SaCas9 recognizes NNGRRT PAM. The engineered VQR, EQR and VRER SpCas9 
variants recognize the NGA, NGAG and NGCG PAMs, respectively (Anders et al., 
2016; Hirano et al., 2016b; Kleinstiver et al., 2015a). The engineered KKH SaCas9 
variant recognizes the NNNRRT PAM (Kleinstiver et al., 2015b). Furthermore, the 
FnCas9 variant was created by structure-guided engineering, and the PAM preference 
was changed from NGR to YG (Hirano et al., 2016a). These Cas9 variants have 
broadened the range of the target sequences selectivity.  
 
In addition, the targeting specificity of Cas9 is one of key factors for the application of 
Cas9 for gene editing tools. Cas9 sometimes targets the off-target sites which resemble 
the on-target sequences (Fu et al., 2013; Hsu et al., 2013). This is the one of the 
problems which impair the expansion of Cas9 for therapeutic usage. The high-fidelity 
Cas9 with almost no detectable genome-wide off-target effects was created by 
structure-guided engineering (Kleinstiver et al., 2016a; Slaymaker et al., 2015). To 
control the timing of activation, split SpCas9s are created. The sprit SpCas9s are 
assembled by sgRNA, fused FKBP (FK506 binding protein 12) and FRB (FKBP 
rapamycin binding) domains, or fused photoinducible dimerization domains, and they 
maintained the activity comparable to WT SpCas9 (Nihongaki et al., 2015; Wright et 
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al., 2015; Zetsche et al., 2015b). Furthermore, Cas9 fused with GFP or other 
fluorescence protein enables the imaging of target DNAs (Chen et al., 2013). Cas9 
fused with transcription activation factors (Konermann et al., 2014; Nishimasu et al., 
2015) and fused with deaminases (Nishida et al., 2016; Komor et al., 2016) are applied 
for the programmable gene editing without double stranded breaks. These Cas9 
relating tools are indispensable in the field of life science.  
 
1.5 Cpf1 
In 2015, Cpf1, a novel effector complex, was discovered, which is classified into the 
class 2 type V CRISPR-Cas system (Zetsche et al., 2015a). Whereas both of Cpf1 and 
Cas9 are effector endonucleases belonging to the class 2 CRISPR-Cas systems, there 
are some differences between them (Figure 1-4). First, Cpf1 is a single-RNA guided 
DNA endonuclease, guided by a crRNA, whereas Cas9 is a dual-RNA guided DNA 
endonuclease, guided by a pair of crRNA and tracrRNA (Deltcheva et al., 2011). 
Second, Cpf1 recognizes a T-rich PAM, whereas Cas9 recognizes the G-rich PAM 
(Fonfara et al., 2014; Karvelis et al., 2015). Third, Cpf1 generates staggered ends in its 
PAM-distal target site (Zetsche et al., 2015a), whereas Cas9 creates blunt ends within  
the PAM-proximal target site (Garneau et al., 2010). Fourth, Cpf1 contains the RuvC 
domain but lacks a detectable second endonuclease domain (Zetsche et al., 2015a), 
whereas Cas9 uses the HNH and RuvC endonuclease domains to cleave the target and 
non-target DNA strands, respectively (Jinek et al., 2012; Gasiunas et al., 2012). Fifth, 
Cpf1 can process its own crRNA array to generate the mature crRNAs (Fonfara et al., 
2016). Sixth, Cpf1 exhibits higher targeting specificity in mammalian cells, as 
compared with Cas9 (Kim et al., 2016a; Kleinstiver et al., 2016b). There was no 
sequence similarity between Cpf1 and Cas9 except the RuvC domains, so the 
prediction of the overall structure of Cpf1 was impossible. Similar to Cs9, Cpf1 shows 
gene targeting activities in eukaryotic cells, so is has been harnessed for novel gene 
editing tools. 
 
To reveal the working mechanisms of Cpf1, the structural information of Cpf1 is 
indispensable. Moreover, it would be possible to generate novel gene editing tools by 
the structural-guided protein engineering. 
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Chapter 2: Crystal structure of Cpf1 in complex 
with guide RNA and target DNA 
 
2.1 Summary 
Cpf1 is an RNA-guided endonuclease of a type V CRISPR-Cas system that has been 
recently harnessed for genome editing. Here, we report the crystal structure of 
Acidaminococcus sp. Cpf1 (AsCpf1) in complex with the guide RNA and its target 
DNA, at 2.8 Å resolution. AsCpf1 adopts a bilobed architecture, with the RNA–DNA 
heteroduplex bound inside the central channel. The structural comparison of AsCpf1 
with Cas9, a type II CRISPR-Cas nuclease, reveals both striking similarity and major 
differences, thereby explaining their distinct functionalities. AsCpf1 contains the RuvC 
domain and a novel nuclease supporting domain. The RuvC domain are responsible for 
the cleavage of both the non-target and target strands and the nuclease supporting 
domain assists the cleavage of the target strand, respectively, and jointly generate 
staggered DNA double-strand breaks. AsCpf1 recognizes the TTTV protospacer 
adjacent motif by base and shape readout mechanisms. Our findings provide 
mechanistic insights into RNA-guided DNA cleavage by Cpf1, and establish a 
framework for rational engineering of the CRISPR-Cpf1 toolbox. 
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2.2 Introduction 
A second class 2 (type V) effector protein, Cpf1, has been harnessed for genome 
editing (Zetsche et al., 2015a). Similar to Cas9, Cpf1 can be reprogrammed to target 
DNA sites of interest through complementarity to a guide RNA. However, Cpf1 
possesses several unique features that distinguish it from Cas9 and could provide for a 
substantial expansion of the genome-editing toolbox. First, Cpf1 is guided by a single 
crRNA, whereas Cas9 uses a crRNA and a second small RNA species, a 
trans-activating crRNA (tracrRNA) (Deltcheva et al., 2011). Second, Cpf1 recognizes 
a T-rich PAM, in contrast to the G-rich PAM favored by Cas9 (Fonfara et al., 2014; 
Karvelis et al., 2015). Third, Cpf1 generates staggered ends in its PAM-distal target 
site (Zetsche et al., 2015a), whereas Cas9 creates blunt ends within the PAM-proximal 
target site (Garneau et al., 2010). Fourth, Cpf1 contains the RuvC domain but lacks a 
detectable second endonuclease domain (Zetsche et al., 2015a), whereas Cas9 uses the 
HNH and RuvC endonuclease domains to cleave the target and non-target DNA 
strands, respectively (Gasiunas et al., 2012; Jinek et al., 2012). Especially the third 
character of Cpf1 is expected to be convenient for non-homologous end joining 
(NHEJ)-based gene insertion. Generating the staggered cut with an overhang could 
enable to identify the proper orientations of the DNA inserts. Together, these 
observations imply major differences in the target DNA recognition and cleavage 
mechanisms between Cas9 and Cpf1.  
 
2.3 Research aims 
To clarify how Cpf1 recognizes and cleaves DNA targets, we determined the crystal 
structure of AsCpf1 in complex with the crRNA and its double-stranded DNA target 
containing the TTTV PAM (V is A, G or C). Moreover, to reveal the structural 
similarity and differences between the two class 2 effector proteins, we compared the 
structure of AsCpf1 and Cas9. The structural comparison explained the distinct 
functionalities and suggested the functional convergence. 
 
2.4 Materials and methods 
2.4.1 Plasmid construction  
The gene encoding full-length Acidaminococcus sp. Cpf1 (AsCpf1, residues 1–1307) 
was PCR-amplified using the pcDNA3.1-AsCpf1 plasmid (Zetsche et al., 2015a) as the 
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template, and cloned between the NdeI and XhoI sites of the modified pE-SUMO 
vector (LifeSensors). The original vector used as the template of PCR was received 
from Dr. Feng Zhang of MIT. The modified pE-SUMO vector contains a N-terminal 
His6-tag followed by a SUMO tag and a tobacco etch virus (TEV) protease cleavage 
site. The plasmid DNAs were amplified in Escherichia coli Mach (Thermo Fisher 
Scientific), cultured in LB medium (Nacalai Tesque) at 37°C overnight. 
 
2.4.2 Expression and purification 
The AsCpf1-expressing E. coli Rosetta2 (DE3) (Novagen) cells were cultured at 37°C 
in LB medium (containing 20 mg/l kanamycin) until the OD600 reached 0.8, and 
protein expression was then induced by the addition of 0.1 mM isopropyl 
β-D-thiogalactopyranoside (IPTG) (Nacalai Tesque). The E. coli cells were further 
cultured at 20°C for 18 h, and harvested by centrifugation at 5,000 g for 10 min. The E. 
coli cells were resuspended in buffer A (50 mM Tris-HCl, pH 8.0, 20 mM imidazole, 
300 mM NaCl and 3 mM 2-mercaptoethanol), lysed by sonication, and then 
centrifuged at 40,000 g for 30 min. The supernatant was mixed with 5 ml Ni-NTA 
Superflow (QIAGEN) equilibrated with buffer A for about 1 hour at 4°C, and the 
mixture was loaded into an Econo-Column (Bio-Rad). The resin was washed with 5 
column volumes of buffer A, 5 column volumes of buffer B (50 mM Tris-HCl, pH 8.0, 
20 mM imidazole, 1 M NaCl and 3 mM 2-mercaptoethanol) and 3 column volumes of 
buffer A. The protein was eluted with buffer C (50 mM Tris-HCl, pH 8.0, 300 mM 
imidazole, 300 mM NaCl and 3 mM 2-mercaptoethanol). The protein was loaded onto 
a HiTrap SP HP column (GE Healthcare) equilibrated with buffer D (20 mM Tris-HCl, 
pH 8.0 and 200 mM NaCl). The column was washed with buffer D, and the protein 
was then eluted with a linear gradient of 200–1,000 mM NaCl. To remove the 
His6-SUMO-tag, the eluted protein was mixed with TEV protease (home made), and 
was dialyzed at 4°C for 12 h against buffer E (20 mM Tris-HCl, pH 8.0, 40 mM 
imidazole, 300 mM NaCl and 3 mM 2-mercaptoethanol). The protein was passed 
through the Ni-NTA column equilibrated with buffer E. The protein was concentrated 
using an Amicon Ultra 10K filter (Millipore), and was further purified by 
chromatography on a HiLoad Superdex 200 16/60 column (GE Healthcare) 
equilibrated with buffer F (10 mM Tris-HCl, pH 8.0, 150 mM NaCl and 1 mM DTT). 
The purified AsCpf1 proteins were stored at −80°C until use. The purified AsCpf1 
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protein was mixed with the crRNA, the target DNA strand, and the non-target DNA 
strand (molar ratio, 1:1.5:2.3:3.4), and then the reconstituted AsCpf1–crRNA–target 
DNA complex was concentrated using an Amicon Ultra 10K filter. The complex was 
purified by gel filtration chromatography on a Superdex 200 Increase column (GE 
Healthcare) equilibrated with buffer F. 
 
2.4.3 crRNA and target DNA construction 
Two crRNAs with different length of the guide sequences (20-nt or 24-nt) were 
designed based on the previous study (Zetsche et al., 2015a). The crRNAs were 
purchased from Gene Design. PAM containing target DNAs were designed to form the 
PAM duplex. We predicted that the length of PAM duplex affects the crystallization of 
the complex, so six target DNAs with different length of the target sequences (20-nt or 
24-nt) and the PAM duplex (8-bp, 9-bp, or 10-bp) were prepared. The target and 
non-target DNA strands were purchased from Sigma-Aldrich. 
 
2.4.4 Crystallization 
The peak fractions of the purified AsCpf1–crRNA–target DNA complex were 
concentrated by Amicon Ultra 10K filter. Using the concentrated complex solution 
(A260 nm = 10), the initial crystallization screening was performed at 20°C by the 
sitting-drop vapor diffusion method. 
 
The screening kits used for the initial screening 
Crystal Screen, PEG/Ion (Hampton Research) 
JBScreen Classic 1, 2, 4, 5 (Jena Bioscience) 
MemGold, MemGold2, JCSG-plus, PACT premier (Molecular Dimensions) 
Wizard Classic 1 and 2 (Emerald Biosystems) 
 
For crystallization optimization, Additive Screen (Hampton Research) was added to 
the reservoir solutions, in addition to the optimization of the concentration of 
precipitations and salt, and pH of the buffers. After the optimization by the sitting-drop 
vapor diffusion method, further optimization was performed by the hanging-drop 
vapor diffusion method. The crystallization drops were formed by mixing 1 µl of 
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complex solution (A260 nm = 10) and 1 µl of reservoir solution, and then were incubated 
against 0.5 ml of reservoir solution. The crystals were improved by micro-seeding 
using Seed Bead (Hampton Research). In the sitting-drop vapor diffusion method, the 
crystallization conditions were prepared using PLATEMASTER P220 (GILSON) and 
Mosquito crystallization robot (TTP Labtech). 
 
2.4.5 X-ray diffraction analysis and data processing 
The native crystals were cryoprotected in a solution consisting of 11% PEG3,350, 100 
mM sodium acetate (pH 4.5), 15% 1,6-hexanediol and 30% ethylene glycol. To reduce 
radiation damage, all X-ray-diffraction data were collected at 100 K on the beamlines 
BL32XU and BL41XU at SPring-8, and PXI X06SA at the Swiss Light Source. A 
diffraction data set was collected from a single crystal using a X-ray beam at a 
wavelength of 1.000 Å, an oscillation range of 180° (0.1° per image), an exposure time 
of 1.0 s per image. The X-ray-diffraction data were processed using DIALS 
(Waterman et al., 2013) and AIMLESS (Evans and Murshudov, 2013). 
 
2.4.6 Crystallization of SeMet-labeled AsCpf1 
The selenomethionine (SeMet)-labeled AsCpf1 protein was expressed in E. coli B834 
(DE3) (Novagen), and purified using a similar protocol as that for the native protein. 
The SeMet-labeled complex was reconstituted and crystallized by mixing 1 µl of 
complex solution (A260 nm = 10) and 1 µl of reservoir solution under similar conditions 
to the native protein. The SeMet-labeled crystals were cryoprotected in a solution 
consisting of 35% PEG400, 100 mM sodium acetate (pH 4.0), 200 mM lithium sulfate 
and 150 mM NaCl. All X-ray-diffraction data were collected at 100 K on the 
beamlines BL41XU at SPring-8, and PXI X06SA at the Swiss Light Source. A 
diffraction data set was collected from a single crystal using a X-ray beam at a 
wavelength of 0.979 Å, an oscillation range of 180° (0.1° per image), an exposure time 
of 1.0 s per image. 
 
2.4.7 Phase determination, model building and structure refinement 
The structure was determined by the Se-SAD method, using PHENIX AutoSol 
(Adams et al., 2010). The structure model was automatically built using Buccaneer 
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(Cowtan, 2006), followed by manual model building using COOT (Emsley and 
Cowtan, 2004) and structural refinement using PHENIX (Adams et al., 2010). 
Structural figures were prepared using CueMol (http://www.cuemol.org). 
 
2.4.8 Generation of the AsCpf1 mutants 
This experiment was performed partly in collaboration with Dr. Feng Zhang (MIT). 
The human codon-optimized AsCpf1 mutants were cloned using the Golden Gate 
strategy (Engler et al., 2009). Briefly, WT AsCpf1 (pY010) was used as the template 
to amplify two PCR fragments, using primers containing the BsmBI restriction sites. 
BsmBI digestion results in distinct 5ʹ′ overhangs that either are compatible with the 
HindIII or XbaI overhangs of the recipient vector or will reconstitute the desired point 
mutation at the junction of the two AsCpf1 DNA pieces. 
 
2.4.9 Cleavage activity of AsCpf1 in HEK293FT cells 
This experiment was performed partly in collaboration with Dr. Feng Zhang (MIT). 
The plasmid expressing the wild type or mutants of AsCpf1 with N- and C-terminal 
nuclear localization tags (400 ng) and the plasmid expressing the crRNA (100 ng) 
were used to transfect human embryonic kidney 293FT cells at 75–90% confluency in 
a 24-well plate, using the Lipofectamine 2000 reagent (Life Technologies). Genomic 
DNA was extracted using QuickExtract™ DNA Extraction Solution (Epicentre). 
Indels were analyzed by deep sequencing, as previously described (Hsu et al., 2013). 
 
2.4.10 Synthesis of crRNA 
This experiment was performed partly in collaboration with Dr. Feng Zhang (MIT). 
The crRNA for in vitro cleavage assay was synthesized using the HiScribe™ T7 High 
Yield RNA Synthesis Kit (NEB). DNA oligos corresponding to the reverse 
complement of the target RNA sequence were synthesized from IDT and annealed to a 
short T7 priming sequence. T7 transcription was performed for 4 hours and then the 
RNA was purified using Agencourt RNAClean XP beads (Beckman Coulter). 
 
2.4.11 Preparation of AsCpf1-containing cell lysate 
This experiment was performed partly in collaboration with Dr. Feng Zhang (MIT). 
HEK293 cells, growing in 6-well plates, were transfected with AsCpf1 expression 
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plasmids (2 µg) using the Lipofectamine 2000 reagent. After 48 hours, the cells were 
harvested by washing with DPBS (Life Technologies) and then were resuspended in 
250 ml of lysis buffer (20 mM HEPES (pH 7.5), 100 mM KCl, 5mM MgCl2, 1 mM 
DTT, 5% glycerol, 0.1% Triton X-100, and 1× cOmplete Protease Inhibitor Cocktail 
Tablets™ (Roche)). After 10 min sonication and 20 min centrifugation (20,000 g), the 
supernatants were frozen for subsequent use in in vitro cleavage assays. 
 
2.4.12 In vitro cleavage assay 
This experiment was performed partly in collaboration with Dr. Feng Zhang (MIT). 
The in vitro cleavage assay was performed with a mammalian cell lysate containing 
either AsCpf1 or SpCas9 protein, at 37°C for 20 min in cleavage buffer (1x 
CutSmart® buffer (NEB), 5 mM DTT). The cleavage reaction used 500 ng of 
synthesized crRNA and 200 ng of target DNA. To prepare the substrate DNA, a 611 
bp region containing the target sequence with the TTTA PAM was amplified by PCR, 
using the pUC19 vector as a template. To generate fluorescent-labeled substrates, PCR 
primers were labeled by the 5ʹ′ EndTag™ Nucleic Acid Labeling System (Vector 
Laboratories); the forward and reverse primers were labeled to generate the labeled 
non-target and target strands, respectively. Reactions were processed with a 
Zymoclean™ Gel DNA Recovery Kit (Zymo Research) and were run on a 10% 
polyacrylamide TBE-Urea gel. The gel was visualized using an Odyssey® CLx 
Imaging System (Li-Cor). For the RuvC domain mutants, the processed reactions were 
run on TBE 6% polyacrylamide or TBE-Urea 6% polyacrylamide gels (Life 
Technologies), and the gels were then stained with SYBR Gold (Invitrogen). 
 
2.5 Results 
2.5.1 Expression and purification 
WT AsCpf1 protein was stable and the expression level was high. Furthermore, WT 
AsCpf1 was highly purified by the combination of the Ni-NTA chromatography, the 
cation exchange chromatography, and the gel filtration chromatography. The gel 
filtration chromatogram peak showed monodispersity (Figures 2-1). The final yield of 
the WT AsCpf1 was 17 mg per 1 L culture medium. 
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2.5.2 Crystallization and X-ray diffraction analysis 
The WT AsCpf1 in complex with a 43-nt crRNA containing 24-nt guide sequence, a 
34-nt target DNA strand, and a 10-nt non-target DNA strand was suitable for 
crystallization (Figure 2-2). In the initial screening, the initial crystals of the complex 
were obtained under the conditions of No. 27 of JB Screen Classic 1, 2, 4, 5 (8% 
PEG4,000, 100 mM sodium acetate pH 4.6) and No. 88 of MemGold (28% PEG400, 
200 mM lithium sulfate, 100 mM sodium citrate pH 3.5) by sitting-drop vapor 
diffusion method. As a result of the optimization of the condition, the crystals suitable 
for the X-ray diffraction analysis were obtained under the two conditions, conditions A 
and B (A : 8–10% PEG3,350, 100 mM sodium acetate (pH 4.5), 10–15% 
1,6-hexanediol, B : 27–30% PEG400, 100 mM sodium acetate (pH 4.0), 200 mM 
lithium sulfate) (Figure 2-3). The 2.8 Å resolution data sets were collected from both 
crystals. 
 
2.5.3 Expression and purification of SeMet-labeled AsCpf1 
The WT AsCpf1 contains 18 methionines, so the single-wavelength anomalous 
diffraction (SAD) method using the SeMet-labeled AsCpf1 is suitable for the phase 
determination. The final yield of the SeMet-labeled AsCpf1 was 2.8 mg per 1 L culture 
medium, which is decreased enormously compared to the native AsCpf1. 
 
2.5.4 Crystallization of SeMet-labeled AsCpf1 
The crystals of the SeMet-labeled complex were obtained under the condition B (27–
30% PEG400, 100 mM sodium acetate (pH 4.0), and 200 mM lithium sulfate) (Figure 
2-4). 
 
2.5.5 Phase determination, model building and structure refinement 
Selenium anomalous dispersions were observed from the crystals of the SeMet-labeled 
complex, so the phase determination was performed by Se-SAD method. When the 
two electron density maps from two crystals are compared each other, the map 
calculated from the data sets of crystal B (obtained under the condition B) contains 
more disorder regions. Therefore, the final structure was refined using the data sets 
collected from crystal A (obtained under the condition A) (2.8 Å resolution, Rwork/Rfree 
= 0.216/0.255) (Figures 2-5). Data collection and refinement statistics are shown in 
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Table 2-1. 
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Table 2-1. Data Collection and Refinement Statistics. 
 
Native SeMet 
Data collection 
 
 
Beamline SLS PXI X06SA SPring-8 BL41XU 
Wavelength (Å) 1.000 0.979 
Space group P212121 P41212 
Cell dimensions 
 
 
a, b, c (Å) 81.5, 136.7, 196.9 191.5, 191.5, 124.2 
α, β, γ (°) 90, 90, 90 90, 90, 90 
Resolution (Å)* 196–2.80 (2.88–2.80) 191–2.8 (2.88–2.80) 
Rmerge 0.089 (0.32) 0.155 (2.08) 
Rpim 0.048 (0.18) 0.030 (0.42) 
I/σI 8.6 (2.2) 22.3 (2.8) 
Completeness (%) 99.0 (99.3) 100 (100) 
Multiplicity 4.4 (4.5) 51.4 (48.6) 
CC(1/2) 0.99 (0.73) 1.00 (0.91) 
   
Refinement 
 
 
Resolution (Å) 56.2–2.8  
No. reflections 54,241  
Rwork / Rfree 0.216 / 0.255  
No. atoms 
 
 
    Protein 10,168  
    Nucleic acid 1,657  
    Ion 1  
    Solvent 37  
B-factors (Å2) 
 
 
    Protein 71.3  
    Nucleic acid 70.8  
    Ion 57.4  
    Solvent 51.9  
R.m.s. deviations 
 
 
    Bond lengths (Å) 0.002  
    Bond angles (°) 0.493  
Ramachandran plot (%) 
 
 
    Favored region 97.0  
    Allowed region 3.0  
    Outlier region 0.0  
*Values in parentheses are for the highest resolution shell. 
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2.5.6 Overall structure of the AsCpf1–crRNA–target DNA complex  
We solved the 2.8 Å resolution crystal structure of the full-length AsCpf1 (residues 1–
1307) in complex with a 43-nt crRNA, a 34-nt target DNA strand, and a 10-nt 
non-target DNA strand containing a TTTA PAM, by the single-wavelength anomalous 
diffraction (SAD) method (Figures 2-6, 2-7 and 2-8). The structure revealed that 
AsCpf1 adopts a bilobed architecture consisting of an α-helical recognition (REC) lobe 
and a nuclease (NUC) lobe, with the crRNA–target DNA heteroduplex bound to the 
positively charged, central channel between the two lobes (Figures 2-6C, 2-6D and 
2-7). The REC lobe consists of the REC1 and REC2 domains, whereas the NUC lobe 
consists of the RuvC domain and three additional domains, denoted A, B and C 
(Figure 2-6C). 
 
A Dali search (Holm and Rosenström, 2010) detected no structural similarity between 
the REC1, REC2, as well as the A, B and C domains, and any of the available protein 
structures. Sequence database searches using PSI-BLAST (Altschul et al., 1997) and 
HHPred (Söding et al., 2005) also failed to detect significant similarity between these 
domains and any protein sequences in the current databases. Thus, these domains of 
Cpf1 have no detectable homologs outside the Cpf1 protein family, and appear to 
adopt novel structural folds (Figures 2-6C and 2-8). The REC1 domain comprises 13 α 
helices, while the REC2 domain comprises 10 α helices and 2 β strands that form a 
small antiparallel sheet (Figures 2-8A and 2-8B). Domains A and B play functional 
roles similar to those of the WED (Wedge) and PI (PAM-interacting) domains of Cas9 
(Anders et al., 2014; Hirano et al., 2016a; Nishimasu et al., 2015), respectively, 
although the two domains of AsCpf1 are structurally unrelated to the WED and PI 
domains (described below). Domain C is involved in DNA cleavage (described below). 
Thus, domains A, B and C are referred to as the WED, PI and Nuc domains, 
respectively. The WED domain is assembled from three separate regions (WED-I–III) 
in the Cpf1 sequence (Figures 2-6A, 2-8A and 2-8C). The WED domain can be 
divided into a core subdomain comprising a 9-stranded, distorted antiparallel β sheet 
(β1–β8 and β11) flanked by 7 α helices (α1–α6 and α9), and a subdomain comprising 2 
β strands (β9–β10) and 2 α helices (α7 and α8) (Figures 2-8A and 2-8C). Examination 
of the Cpf1 sequence alignment revealed that helices α7 and α8 are not conserved 
among Cpf1 homologs (Zetsche et al., 2015a) (Figure 2-9). The PI domain comprises 
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7α helices (α1–α7) and a β hairpin (β1 and β2), and is inserted between the WED-II 
and WED-III regions, whereas the REC lobe is inserted between the WED-I and 
WED-II regions (Figures 2-6A and 2-8A and 2-8B). As discussed previously (Zetsche 
et al., 2015a), the RuvC domain contains the three motifs (RuvC-I–III) that form the 
endonuclease active center. A characteristic helix (referred to as the bridge helix) is 
located between the RuvC-I and RuvC-II motifs, and connects the REC and NUC 
lobes (described below) (Figures 2-6A, 2-6C and 2-6D). The Nuc domain is inserted 
between the RuvC-II and RuvC-III motifs. 
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2.5.7 Structure of crRNA and target DNA 
The crRNA consists of the 24-nt guide segment (G1–C24) and the 19-nt scaffold 
(A(−19)–U(−1)) (referred to as the 5ʹ′-handle) (Figures 2-10A and 2-10B). The 
nucleotides G1–C20 in the crRNA and dC1–dG20 in the target DNA strand form the 
20-bp RNA–DNA heteroduplex (Figures 2-10A and 2-10B). The nucleotide A21 in the 
crRNA is flipped out and adopts a single-stranded conformation. No electron density 
was observed for the nucleotides A22–C24 in the crRNA and dT21–dG24 in the target 
DNA strand, suggesting that these regions are flexible and disordered in the crystal 
structure. The nucleotides dG(−10)–dT(−1) in the target DNA strand and dC(−10*)–
dA(−1*) in the non-target DNA strand form a duplex structure (referred to as the PAM 
duplex) (Figures 2-10A and 2-10B). 
 
The crystal structure revealed that the crRNA 5ʹ′-handle adopts a pseudoknot structure, 
rather than a simple stem-loop structure predicted from its nucleotide sequence 
(Zetsche et al., 2015a) (Figures 2-10A and 2-10C). Specifically, the G(−6)–A(−2) and 
U(−15)–C(−11) in the 5ʹ′-handle form a stem structure, via five Watson-Crick base 
pairs (G(−6):C(−11)–A(−2):U(−15)), whereas C(−9)–U(−7) in the 5ʹ′-handle adopt a 
loop structure. U(−1) and U(−16) form a non-canonical U•U base pair (Figure 2-11A). 
U(−10) and A(−18) form a reverse Hoogsteen A•U base pair, and participate in 
pseudoknot formation. The O4 and the 2ʹ′-OH of U(−10) hydrogen bond with the 
2ʹ′-OH and the N1 of A(−19), respectively (Figure 2-11B). In addition, the N3 and the 
O4 of U(−17) hydrogen bond with the O4 of U(−13) and the N6 of A(−12), 
respectively, thereby stabilizing the pseudoknot structure (Figure 2-11C). Importantly, 
U(−1), U(−10), U(−16) and A(−18) in the crRNA are conserved among the 
CRISPR-Cpf1 systems (Zetsche et al., 2015a), indicating that Cpf1 crRNAs form 
similar pseudoknot structures. 
 
2.5.8 Recognition of the 5ʹ′-handle of the crRNA 
The 5ʹ′-handle of the crRNA is bound at the groove between the WED and RuvC 
domains (Figure 2-11D). The U(−1)•U(−16) base pair in the 5ʹ′-handle is recognized by 
the WED domain in a base-specific manner. U(−1) and U(−16) hydrogen bond with 
His761 and Arg18/Asn759, respectively, while U(−1) stacks on His761 (Figure 2-11E). 
These interactions explain the previous finding that the U•U base pair at this position 
43  
is critical for the Cpf1-mediated DNA cleavage (Zetsche et al., 2015a). The N6 of 
A(−19) hydrogen bonds with Leu807 and Asn808, while the base moieties of A(−18) 
and A(−19) form stacking interactions with Ile858 and Met806, respectively (Figure 
2-11F). Moreover, the phosphodiester backbone of the 5ʹ′-handle forms an extensive 
network of interactions with the WED and RuvC domains (Figure 2-12). The residues 
involved in the crRNA 5ʹ′-handle recognition are largely conserved in the Cpf1 protein 
family (Zetsche et al., 2015a) (Figure 2-9), highlighting the functional relevance of the 
observed interactions between AsCpf1 and the crRNA. 
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2.5.9 Recognition of the crRNA–target DNA heteroduplex 
The crRNA–target DNA heteroduplex is accommodated within the positively charged, 
central channel formed by the REC1, REC2, and RuvC domains, and is recognized by 
the protein in a sequence-independent manner (Figures 2-7, 2-12 and 2-13). The 
PAM-distal and PAM-proximal regions of the heteroduplex are recognized by the 
REC1-REC2 domains and the WED-REC1-RuvC domains, respectively (Figures 2-12, 
2-13 and 2-14). Arg951 and Arg955 in the bridge helix and Lys968 in the RuvC 
domain, which interact with the phosphate backbone of the target DNA strand (Figure 
2-13B), are conserved among the Cpf1 family members (Zetsche et al., 2015a) (Figure 
2-9). Notably, the sugar-phosphate backbone of the nucleotides G1–A8 in the crRNA 
forms multiple contacts with the WED and REC1 domains (Figures 2-12 and 2-14A), 
and the base pairing within the 5-bp PAM-proximal, “seed” region is important for 
Cpf1-mediated DNA cleavage (Zetsche et al., 2015a). These observations suggest that, 
in the Cpf1–crRNA complex, the seed of the crRNA guide is preordered in a nearly 
A-form conformation and serves as the nucleation site for pairing with the target DNA 
strand, as observed in the Cas9–sgRNA complex (Jiang et al., 2015). In addition, the 
backbone phosphate group between dT(−1) and dC1 of the target DNA strand (referred 
to as the +1 phosphate) is recognized by the side chain of Lys780 and the main-chain 
amide group of Gly783 (Figure 2-14A). This interaction results in the rotation of the 
+1 phosphate group, thereby facilitating base pairing between dC1 in the target DNA 
strand and G1 in the crRNA, as also observed in the Cas9–sgRNA–target DNA 
complexes (Anders et al., 2014; Nishimasu et al., 2015). The residues involved in the 
heteroduplex recognition are conserved in most members of the Cpf1 family (Zetsche 
et al., 2015a) (Figure 2-9), and the R176A, R192A, G783P and R951A mutants 
exhibited reduced activities (Figure 2-14B), confirming their functional relevance. 
Together, these observations reveal the RNA-guided DNA recognition mechanism of 
Cpf1. 
 
Unexpectedly, the present structure revealed that the 24-nt crRNA guide and the target 
DNA strand form a 20-bp, rather than 24-bp, RNA–DNA heteroduplex (Figure 2-13A). 
The side chain of Trp382 in the REC2 domain forms a stacking interaction with the 
C20:dG20 base pair in the heteroduplex, and thus prevents base pairing between A21 
and dT21 (Figure 2-14C). Indeed, the W382A mutant showed reduced activity (Figure 
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2-14B), highlighting its functional importance. Trp382 is conserved in some members 
of the Cpf1 family, whereas others contain aromatic residues in this position (Zetsche 
et al., 2015a) (Figure 2-9). These observations indicate that Cpf1 recognizes the 20-bp 
RNA–DNA heteroduplex, and can explain the previous finding that the Francisella 
novicida U112 Cpf1 (FnCpf1) cleaved the target DNA in a similar manner, using 
either the 20-nt or 24-nt guide-containing crRNA (Zetsche et al., 2015a). 
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2.5.10 Recognition of the TTTV PAM 
The PAM duplex adopts a distorted conformation with a narrow minor groove, as 
often observed in AT-rich DNA (Rohs et al., 2009; Stella et al., 2010), and is bound to 
the groove formed by the WED, REC1 and PI domains (Figures 2-15A and 2-15B). 
The PAM duplex is recognized by the WED, REC1 and PI domains from the major 
and minor groove sides, respectively (Figure 2-15C). The dT(−1):dA(−1*) base pair in 
the PAM duplex does not form base-specific contacts with the protein (Figures 2-15). 
Although the distorted shape of the PAM duplex is predicted to affects the preference 
for V in the 4th position, the mechanisms for the specificity was not fully explained 
based on this structure. Lys607 in the PI domain is inserted into the narrow minor 
groove, and plays critical roles in the PAM recognition (Figure 2-15C). The O2 of 
dT(−2*) forms a hydrogen bond with the side chain of Lys607, whereas the nucleobase 
and deoxyribose moieties of dA(−2) form van der Waals interactions with the side 
chains of Lys607 and Pro599/Met604, respectively (Figure 2-16A). Modeling of the 
dG(−2):dC(−2*) base pair indicated that a steric clash exists between the N2 of dG(−2) 
and the side chain of Lys607 (Figure 2-16D), suggesting that dA(−2):dT(−2*), but not 
dG(−2):dC(−2*), is accepted at this position. These structural observations can explain 
the requirement of the 3rd T in the TTTV PAM. The 5-methyl group of dT(−3*) forms 
a van der Waals interaction with the side-chain methyl group of Thr167, whereas the 
N3 and N7 of dA(−3) form hydrogen bonds with Lys607 and Lys548, respectively 
(Figure 2-16B). Modeling of the dG(−3):dC(−3*) base pair indicated that a steric clash 
exists between the N2 of dG(−3) and the side chain of Lys607 (Figure 2-16E). These 
observations are consistent with the requirement of the 2nd T in the PAM. The 
5-methyl group of dT(−4*) is surrounded by the side-chain methyl groups of Thr167 
and Thr539, whereas the O4ʹ′ of dA(−4) forms a hydrogen bond with the side chain of 
Lys607 (Figure 2-16C). Notably, the N3 and O4 of dT(−4*) form hydrogen bonds with 
the N1 of dA(−4) and the N6 of dA(−3), respectively (Figure 2-16C). Modeling 
indicated that dA(−3) would sterically clash with the modeled base pairs, 
dT(−4):dA(−4*), dG(−4):dC(−4*) and dC(−4):dG(−4*) (Figure 2-16F). These 
structural observations are consistent with the requirement of the 1st T in the PAM. 
The K548A and M604A mutants exhibited reduced activities (Figure 2-16G), 
confirming that Lys548 and Met604 participate in the PAM recognition. More 
importantly, the K607A mutant showed almost no activity (Figure 2-16G), indicating 
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that Lys607 is critical for the PAM recognition. Together, these results demonstrate 
that AsCpf1 recognizes the TTTV PAM via a combination of base and shape readout 
mechanisms. Thr167 and Lys607 are conserved throughout the Cpf1 family, and 
Lys548, Pro599, and Met604 are partially conserved (Zetsche et al., 2015a) (Figure 
2-9). These observations indicate that the Cpf1 homologs from diverse bacteria 
recognize their T-rich PAMs in similar manners, although the fine details of the 
interaction could vary. 
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2.5.11 The RuvC-like endonuclease and the supporting domain 
The RuvC domain comprises a typical RNase H fold, consisting of a 5-stranded mixed 
β-sheet (β1–β5) flanked by 3 α helices (α1–α3), and 2 additional α helices and a β 
strand (Figure 2-17A). The conserved, negatively charged residues, Asp908, Glu993 
and Asp1263, form an active site similar to that of the Cas9 RuvC domain (Nishimasu 
et al., 2014; Anders et al., 2014) (Figure 2-17B). As observed in FnCpf1 (Zetsche et al., 
2015a), the D908A and E993A mutants had almost no activity, whereas the D1263A 
mutant exhibited significantly reduced activity (Figure 2-17C), confirming the roles of 
Asp908, Glu993 and Asp1263 in DNA cleavage. Notably, the bridge helix is inserted 
between strand β3 and helix α1 in the RNase H fold, and interacts with the REC2 
domain (Figures 2-17A, 2-18A and 2-18B). The main-chain carbonyl group of Gln956 
in the bridge helix forms a hydrogen bond with the side chain of Lys468 in the REC2 
domain (Figure 2-18B). In addition, Trp958 in the RuvC domain is accommodated in 
the hydrophobic pocket formed by Leu467, Leu471, Tyr514, Arg518, Ala521 and 
Thr522 in the REC2 domain (Figure 2-18B). These residues, with the exceptions of 
Leu467 and Ala521, are highly conserved among the Cpf1 family members (Zetsche et 
al., 2015a) (Figure 2-9), and the W958A mutant exhibited reduced activity (Figure 
2-17C). These observations highlight the functional importance of the bridge 
helix-mediated interaction between the REC and NUC lobes. 
 
The crystal structure revealed the presence of the Nuc domain, which is inserted 
between the RuvC-II (strand β5) and RuvC-III (helix α3) motifs in the RuvC domain. 
The Nuc domain is connected to the RuvC domain via two linker loops (referred to as 
L1 and L2) (Figure 2-17A). The Nuc domain comprises 5 α helices and 9 β strands, 
and lacks detectable structural or sequence similarity to any known nucleases or 
proteins. Notably, the conserved polar residues, Arg1226 and Asp1235, and the 
partially conserved Ser1228, are clustered in the proximity of the active site of the 
RuvC domain (Zetsche et al., 2015a) (Figures 2-9 and 2-17B). The S1228A mutant 
showed DNA cleavage activity comparable to that of the WT AsCpf1 (Figure 2-17C). 
In contrast, the D1235A mutant exhibited reduced activity, whereas the R1226A 
mutant showed almost no activity (Figure 2-17C), indicating that Arg1226 is critical 
for DNA cleavage. Further characterization revealed that the R1226A mutant acts as a 
nickase that cleaves the non-target DNA strand but not the target strand (Figure 2-18C), 
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indicating that the RuvC domain cleave the non-target DNA strand and the Nuc 
domain is indispensable for the cleavage of the target DNA strand (Figure 2-18A). As 
in FnCpf1 (Zetsche et al., 2015a), the mutations of the catalytic residues in the AsCpf1 
RuvC domain abolished the cleavage of both DNA strands (Figure 19). The Nuc 
domain is predicted not a nuclease domain, suggesting that the Nuc domain do not 
cleave the target DNA strand, but guide the strand to the catalytic center of the RuvC 
domain. However, further functional and structural studies are required to fully 
characterize the RNA-guided DNA cleavage mechanism of Cpf1. 
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2.6 Discussion 
The present structure of the AsCpf1–crRNA–target DNA complex provides 
mechanistic insights into the RNA-guided DNA cleavage by Cpf1. The structural 
comparison between Cpf1 and Cas9, the only available structures of class 2 (single 
protein) effectors, illuminated the considerable similarity in their overall architectures, 
which was unanticipated given the lack of sequence similarity outside the RuvC 
domain (Figures 2-20A–2-20D). Both effector proteins are roughly the same size and 
adopt distinct bilobed structures, in which the two lobes are connected by the 
characteristic bridge helix and the crRNA–target DNA heteroduplex is accommodated 
in the central channel between the two lobes (Figures 2-20A and 2-20B). However, 
despite this overall similarity, only the RuvC nuclease domains of Cas9 and Cpf1 are 
homologous, whereas the rest of the proteins share neither sequence nor structural 
similarity. 
 
One of the striking features of the Cas9 structure is the nested arrangement of the two 
unrelated HNH and RuvC nuclease domains, which cleave the target and non-target 
DNA strands, respectively (Figures 2-20A and 2-20C). In Cas9, the HNH domain is 
inserted between strand β4 and helix α1 of the RNase H fold in the RuvC domain 
(Nishimasu et al., 2014; Anders et al., 2014) (Figure 2-20E). In contrast, Cpf1 lacks 
the HNH domain and instead contains the Nuc domain, which is inserted at a different 
position (albeit also between the RuvC-II and RuvC-III motifs); i.e., between strand β5 
and helix α3 of the RNase H fold (Figure 2-20F). The Nuc domain is relatively poorly 
conserved within the Cpf1 family and lacks sequence or structural similarity to any 
characterized nuclease (or any other protein outside the Cpf1 family). Our mutational 
analysis suggested that the Nuc domain is a ssDNA guiding domain responsible for the 
target DNA strand cleavage. Notably, the position of the Nuc domain of Cpf1 is 
reasonable to explain the role as a guide for the single-stranded region of the target 
DNA strand outside the heteroduplex and creating the staggered cleavage site with the 
4 base overhang (Figures 2-20B and 2-20D), whereas the HNH domain of Cas9 
cleaves the target DNA strand within the heteroduplex (Jinek et al., 2012; Gasiunas et 
al., 2012) (Figure 2-20C). These structural differences can also explain why Cpf1 
induces a staggered DNA double-strand break in the PAM-distal site, whereas Cas9 
creates a blunt end in the PAM-proximal site (Zetsche et al., 2015a). Unlike 
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Streptococcus pyogenes Cas9 (SpCas9), in which inactivation of the RuvC nuclease 
turns the enzyme into a nickase cleaving the target strand, an active RuvC domain is 
required for the cleavage of both strands by AsCpf1 (Figure 2-18C), suggesting further 
conformational changes of Cpf1 to cleave both DNA strands by single nuclease 
domain. Together, these findings indicate that, despite the overall structural similarity, 
there are substantial mechanistic differences between SpCas9 and AsCpf1. Further 
biochemical and structural studies with different members of the Cas9 and Cpf1 
families are required to determine the generality of these distinctions between the two 
effector proteins and to completely elucidate the catalytic mechanism of Cpf1. 
Especially, the previous report showed that the cleavage site of the target DNA strand 
is defined strictly (Zetsche et al., 2015a), and the guiding mechanism by the Nuc 
domain is predicted insufficient to explain the selection of the cleavage site of the 
target DNA strand. In SpCas9, the HNH–RuvC III linker acts as switch, and it 
communicates the conformational changes of the HNH domain to the RuvC domain, 
which is necessary to activate the RuvC domain for cleavage (Sternberg et al., 2015). 
In AsCpf1, although the conformational changes induced by the target DNA cleavage 
are not reported yet, there are possibilities that conformational changes and 
communications between domains may exist and assist in defining the cleavage site 
strictly and cleaving the both DNA strands by single nuclease domain. 
 
The structural comparison between Cpf1 and Cas9 revealed a striking degree of 
apparent structural and functional convergence between Cpf1 and Cas9, which is 
compatible with the previously proposed scenario of independent evolution of the 
effectors in the different types and subtypes of class 2 (Shmakov et al., 2015). 
Intriguingly, Cpf1 and Cas9 employ distinct structural features and recognize the seed 
region in the crRNA and the +1 phosphate group in the target DNA to achieve 
RNA-guided DNA targeting. In Cas9, the seed region is anchored by an arginine 
cluster in the bridge helix between the RuvC and REC domains, whereas the +1 
phosphate group is recognized by the “phosphate lock” loop between the RuvC and 
WED domains (Anders et al., 2014; Nishimasu et al., 2015) (Figure 2-21A). In 
contrast, in Cpf1, the seed region is anchored by the WED and REC domains, whereas 
the + 1 phosphate group is recognized by the WED domain (Figure 2-21B). Structural 
analyses of additional class 2 effectors as well as the transposon-encoded TnpB 
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proteins, which appear to be the evolutionary ancestors of the RuvC domains in the 
type II and type V effectors (Shmakov et al., 2015), are expected to shed further light 
on the evolution of this remarkable class of RNA-guided endonucleases. 
 
The AsCpf1 structure also revealed notable differences in the PAM recognition 
mechanism between Cpf1 and Cas9. In Cas9, the PAM nucleotides in the non-target 
DNA strand are primarily read out from the major groove side, via hydrogen-bonding 
interactions with specific residues in the PI domain. In SpCas9, the 2nd G and 3rd G in 
the NGG PAM are recognized by Arg1333 and Arg1335 in the PI domain, via 
bidentate hydrogen bonds, respectively (Anders et al., 2014) (Figure 2-21A and 
2-22A). In contrast, in AsCpf1, the PAM nucleotides in both the target and non-target 
DNA strands are read out by the PI domain from both the minor and major groove 
sides. In particular, as observed in other protein–DNA complexes (Rohs et al., 2009; 
Stella et al., 2010), the conserved lysine residue (Lys607 in AsCpf1) in the PI domain 
is inserted into the narrow minor groove of the PAM duplex, and plays critical roles in 
the PAM recognition (Figure 2-21B and 2-22B). These structural observations show 
that, whereas Cas9 recognizes the PAM primarily via a base readout mechanism, Cpf1 
combines base and shape readout to recognize the PAM. These mechanistic 
differences in the PAM recognition can explain why Cas9 orthologs recognize G-rich, 
diverse PAM sequences, while the widely different members of the Cpf1 family 
recognize similar T-rich PAMs (Zetsche et al., 2015a). 
 
In summary, the present structure of AsCpf1, combined with the mutational analysis of 
the RuvC and Nuc domains, provides mechanistic insights into the RNA-guided DNA 
recognition and cleavage by this recently discovered CRISPR-Cas effector protein, and 
highlights the similarity and differences between the type V (Cpf1) and type II (Cas9) 
effectors. The structural analysis of Cas9 has enabled the design of numerous Cas9 
variants with improved features and novel functions. Thus, the structural information 
described here will facilitate the engineering of Cpf1, and further increase the utility of 
the CRISPR-Cpf1 toolbox. 
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Chapter 3: Structural basis for the altered PAM 
recognition by engineered CRISPR-Cpf1 
 
3.1 Summary 
The RNA-guided Cpf1 nuclease cleaves double-stranded DNA targets complementary 
to the CRISPR RNA (crRNA), and has been harnessed for genome editing 
technologies. Recently, Acidaminococcus sp. BV3L6 (AsCpf1) was engineered to 
recognize altered DNA sequences as the protospacer adjacent motif (PAM), thereby 
expanding the target range of Cpf1-mediated genome editing. Whereas WT AsCpf1 
recognizes the TTTV PAM, the RVR (S542R/K548V/N552R) and RR 
(S542R/K607R) variants can efficiently recognize the TATV and TYCV PAMs, 
respectively. However, their PAM recognition mechanisms remained unknown. Here, 
we present the 2.0 Å resolution crystal structures of the RVR and RR variants bound to 
a crRNA and its target DNA. The structures revealed that the RVR and RR variants 
primarily recognize the PAM-complementary nucleotides via the substituted residues. 
Our high-resolution structures delineated the altered PAM recognition mechanisms of 
the AsCpf1 variants, providing a basis for the further engineering of CRISPR-Cpf1. 
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3.2 Introduction 
The crystal structure of the AsCpf1–crRNA–target DNA complex provided 
mechanistic insights into the crRNA-guided DNA recognition and cleavage (Yamano 
et al., 2016; Gao et al., 2016). AsCpf1 adopts a bilobed architecture that 
accommodates the crRNA–target DNA heteroduplex. The PAM-containing DNA 
duplex adopts a distorted conformation characteristic of an AT-rich DNA duplex, and 
is recognized by AsCpf1 via the base and shape readout mechanisms (Yamano et al., 
2016). The RuvC and Nuc domains are located at positions suitable to induce 
staggered DNA double-strand breaks at the PAM-distal positions. A structural 
comparison of the AsCpf1–crRNA–target DNA ternary complex (Gao et al., 2016; 
Yamano et al., 2016) with the LbCpf1–crRNA binary complex (Dong et al., 2016) 
indicated a structural rearrangement accompanying the crRNA–target DNA 
heteroduplex formation. Furthermore, a structural comparison of Cpf1 with Cas9 
explained their distinct functionalities, and suggested the functional convergence 
between the class 2 CRISPR-Cas effector nucleases (Yamano et al., 2016). 
 
Recently, a structure-guided mutagenesis screen identified two AsCpf1 variants with 
altered PAM specificities (Gao et al., 2017). The RVR variant contains three 
substitutions (S542R/K548V/N552R), and efficiently cleaves target sites with the 
non-canonical TATV PAM, in addition to those with the canonical TTTV PAM. In 
contrast, the RR variant contains two substitutions (S542R/K607R), and cleaves target 
sites with the non-canonical TYCV PAM, including the T-less CCCC PAM. 
Importantly, these two AsCpf1 variants showed robust activities in human cells, thus 
contributing to the expansion of target spaces in Cpf1-mediated genome editing; 
however, the altered PAM recognition mechanisms of these variants remained 
unknown. It is particularly interesting to determine how the K607R substitution 
contributes to the altered PAM recognition by the RR variant, since Lys607 in the PI 
(PAM-interacting) domain is critical for the TTTV PAM recognition by WT AsCpf1 
(Yamano et al., 2016). It is also unknown how the S542R substitution functions in the 
distinct PAM recognitions by the RVR and RR variants. In addition, the means by 
which the K548V and N552R substitutions participate in the altered PAM recognition 
by the RVR variant are not readily predictable. 
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3.3 Research aims 
Here, to reveal how the AsCpf1 variants achieve the altered the PAM recognition, we 
present the high-resolution crystal structures of the RVR and RR variants of AsCpf1 in 
complexes with the crRNA and its target DNA with the altered PAMs. Furthermore, 
we try to reveal similarities and differences in the altered PAM recognition 
mechanisms between the AsCpf1 and SpCas9 variants by a structural comparison. 
 
3.4 Materials and methods 
3.4.1 Sample preparation 
WT AsCpf1 and the RVR and RV variants were prepared essentially as described 
previously (Yamano et al., 2016). The gene encoding full-length AsCpf1 (residues 1–
1307) was cloned into the modified pE-SUMO vector (LifeSensors), and the mutations 
(S542R, K548V, N552R and K607R) were introduced by a PCR-based method. The 
plasmid DNAs were amplified in Escherichia coli Mach (Thermo Fisher Scientific), 
cultured in LB medium (Nacalai Tesque) at 37°C overnight. The AsCpf1-expressing E. 
coli Rosetta2 (DE3) cells were cultured at 37°C in LB medium (containing 20 mg/l 
kanamycin) until the OD600 reached 0.8, and protein expression was then induced by 
the addition of 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) (Nacalai Tesque). 
The E. coli cells were further cultured at 20°C for 18 h, and harvested by 
centrifugation at 5,000 g for 10 min. The E. coli cells were resuspended in buffer A 
(50 mM Tris-HCl, pH 8.0, 20 mM imidazole, 300 mM NaCl and 3 mM 
2-mercaptoethanol), lysed by sonication, and then centrifuged at 40,000 g for 30 min. 
The supernatant was mixed with 5 ml Ni-NTA Superflow (QIAGEN) equilibrated with 
buffer A for about 1 hour at 4°C, and the mixture was loaded into an Econo-Column 
(Bio-Rad). The resin was washed with 5 column volumes of buffer A, 5 column 
volumes of buffer B (50 mM Tris-HCl, pH 8.0, 20 mM imidazole, 1 M NaCl and 3 
mM 2-mercaptoethanol) and 3 column volumes of buffer A. The protein was eluted 
with buffer C (50 mM Tris-HCl, pH 8.0, 300 mM imidazole, 300 mM NaCl and 3 mM 
2-mercaptoethanol). The protein was loaded onto a HiTrap SP HP column (GE 
Healthcare) equilibrated with buffer D (20 mM Tris-HCl, pH 8.0 and 200 mM NaCl). 
The column was washed with buffer D, and the protein was then eluted with a linear 
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gradient of 200–1,000 mM NaCl. To remove the His6-SUMO-tag, the eluted protein 
was mixed with TEV protease (home made), and was dialyzed at 4°C for 12 h against 
buffer E (20 mM Tris-HCl, pH 8.0, 40 mM imidazole, 300 mM NaCl and 3 mM 
2-mercaptoethanol). The protein was passed through the Ni-NTA column equilibrated 
with buffer E. The protein was concentrated using an Amicon Ultra 10K filter 
(Millipore), and was further purified by a HiLoad Superdex 200 16/60 column (GE 
Healthcare) equilibrated with buffer F (10 mM Tris-HCl, pH 8.0, 150 mM NaCl and 1 
mM DTT). The purified AsCpf1 proteins were stored at −80°C until use. The crRNA 
and target DNA were purchased from Gene Design and Sigma-Aldrich, respectively. 
The purified AsCpf1 protein was mixed with the crRNA, the target DNA strand and 
the non-target DNA strand (molar ratio, 1:1.5:2.3:2.3), and the reconstituted complex 
was concentrated using an Amicon Ultra 10K filter. The AsCpf1–crRNA–target DNA 
complex was purified by gel filtration chromatography on a Superdex 200 Increase 
column (GE Healthcare) equilibrated with buffer F. 
 
3.4.2 In vitro cleavage assay 
In vitro cleavage experiments were performed as previously described (Nishimasu et 
al., 2015), with minor modifications. The target pUC119 plasmids with the different 
PAMs were generated by a PCR-based method. The plasmid DNAs were amplified in 
Escherichia coli Mach (Thermo Fisher Scientific), cultured in LB medium (Nacalai 
Tesque) at 37°C overnight. The EcoRI-linearized pUC119 plasmid (100 ng), 
containing the 24-nt target sequence and the PAMs, was incubated at 37°C for 5 or 10 
min with the AsCpf1–crRNA complex (100 nM), in 10 µl of reaction buffer containing 
20 mM HEPES-NaOH, pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM DTT and 5% 
glycerol. The reaction was stopped by the addition of a solution containing EDTA (40 
mM final concentration) and Proteinase K (10 µg). Reaction products were resolved on 
an ethidium bromide-stained 1% agarose gel, and then visualized using an Amersham 
Imager 600 (GE Healthcare). In vitro cleavage experiments were performed at 
least three times, and representative results were shown. 
 
3.4.3 Crystallization 
The peak fractions of the purified AsCpf1–crRNA–target DNA complex were 
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concentrated by Amicon Ultra 10K filter (A260 nm = 10). The complex was crystallized 
at 20°C, by the hanging-drop vapor diffusion method. The crystallization drops were 
formed by mixing 1 µl of complex solution (A260 nm = 10) and 1 µl of reservoir 
solution (7–10% PEG 3,350, 100 mM sodium acetate, pH 4.5, and 10% 
1,6-hexanediol), and then were incubated against 0.5 ml of reservoir solution. 
 
3.4.4 X-ray diffraction analysis and data processing 
The crystals were cryoprotected in a solution consisting of 9–10% PEG 3,350, 100 
mM sodium acetate, pH 4.5, 10–15% 1,6-hexanediol and 30% ethylene glycol. To 
reduce radiation damage, all X-ray-diffraction data were collected at 100 K on the 
beamline BL41XU at SPring-8. A diffraction data set was collected from a single 
crystal using a X-ray beam at a wavelength of 1.000 Å, an oscillation range of 180° 
(0.1° per image), an exposure time of 1.0 s per image. The X-ray-diffraction data were 
processed using DIALS (Waterman et al., 2013) and AIMLESS (Evans and 
Murshudov, 2013). 
 
3.4.5 Phase determination, model building and structure refinement 
The structures were determined by molecular replacement with Molrep (Vagin and 
Teplyakov, 2010), using the coordinates of WT AsCpf1 (PDB: 5B43) (Yamano et al., 
2016) as the search model. The model building and structural refinement were 
performed using COOT (Emsley and Cowtan, 2004) and PHENIX (Adams et al., 
2010), respectively. Structural figures were prepared using CueMol 
(http://www.cuemol.org). 
 
3.5 Results 
3.5.1 Sample preparation 
The RVR and RR variants were highly purified by the same strategy for the 
purification of WT AsCpf1. The gel filtration chromatogram peaks showed 
monodispersity (Figures 3-1). The final yield of the RVR and RR variants were 11.4 
mg and 14.9 mg per 1 L culture medium, respectively. 
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3.5.2 In vitro cleavage activities of the AsCpf1 variants 
In a previous study, the PAM specificities of the two AsCpf1 variants were determined 
by a PAM identification assay, in which AsCpf1-expressing HEK293T cell lysates 
were incubated with the crRNA and a library of plasmids containing a constant target 
sequence and a degenerate PAM (Gao et al., 2017). We thus evaluated the in vitro 
cleavage activities of the purified RVR and RR variants toward plasmid DNA 
substrates containing a 24-nt target sequence and different potential PAMs. 
 
Since the RVR variant efficiently cleaved target sites with the TATV PAM (Gao et al., 
2017), we examined the ability of the RVR variant to cleave 13 plasmid DNA targets 
with either NATA, TNTA, TANA or TATN as the potential PAM (Figures 3-2A and 
3-3A). The RVR variant efficiently cleaved the TATA target site, as compared with 
the VATA (V is A, G or C) target sites (Figures 3-2A and 3-3A), confirming the 
preference for the first T in the TATV PAM. In addition to the altered TATA PAM, 
the RVR variant efficiently recognized the canonical TTTA PAM (Figures 3-2A and 
3-3A), consistent with a previous study (Gao et al., 2017) (also described below). The 
RVR variant was almost inactive toward the TSTA (S is G or C) and TARA (R is A or 
G) sites, and less active toward the TACA site (Figures 3-2A and 3-3A). These results 
confirmed the strong preference of the second A and the third T for the TATV PAM 
recognition by the RVR variant. The RVR variant was less active toward the TATT 
site, as compared with the TATV sites (Figures 3-2A and 3-3A), indicating the 
preference for the fourth V. These results demonstrated that the RVR variant 
efficiently recognizes TATV and TTTV as the PAM, consistent with a previous study 
(Gao et al., 2017). 
 
Since the RR variant efficiently cleaved target sites with the TYCV PAM (Y is T or C) 
(Gao et al., 2017), we examined the RR variant for the ability to cleave 13 plasmid 
DNA targets with either NCCC, TNCC, TCNC or TCCN as the potential PAM 
(Figures 3-2B and 3-3B). The RR variant efficiently cleaved the TCCC site, as 
compared to the VCCC sites (Figures 3-2B and 3-3B), indicating the preference for the 
first T in the TYCV PAM. The RR variant efficiently cleaved the TYCC sites, but not 
the TRCC sites (Figures 3-2B and 3-3B), confirming the preference of the second Y 
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for the PAM recognition by the RR variant. The RR variant was almost inactive 
toward the TCDC PAMs (D is A, T or G) (Figures 3-2B and 3-3B), confirming the 
strong preference of the third C for the PAM recognition by the RR variant. The RR 
variant was much less active toward the TCCT site, as compared with the TCCV sites 
(Figures 3-2B and 3-3B), indicating the preference for the fourth V. These results 
confirmed that the RR variant efficiently recognizes TYCV as the PAMs, consistent 
with earlier observations (Gao et al., 2017). 
 
The RVR variant recognizes the TTTV PAM as well as the TATV PAM, whereas the 
RR variant is less active towards the TTTV PAM (Gao et al., 2017). We thus 
examined the in vitro cleavage activities of WT AsCpf1 and the RVR and RV variants 
towards four plasmid targets with the TTTN PAMs (Figures 3-2C and 3-3C). WT 
AsCpf1 and the RVR variants efficiently cleaved the TTTV sites, as compared with 
the TTTT site (Figures 3-2C and 3-3C), consistent with previous studies (Gao et al., 
2017; Kim et al., 2016b; Zetsche et al., 2015a). The RR variant was less active toward 
the TTTV sites, as compared with WT AsCpf1 and the RVR variant (Figures 3-2C and 
3-3C). In stark contrast to the RVR and RR variants, WT AsCpf1 exhibited no or little 
activity toward the TATV and TYCV sites (Figures 3-4), highlighting the substantial 
differences in the PAM specificities between WT AsCpf1 and the two AsCpf1 variants. 
Together, our in vitro cleavage experiments confirmed that, unlike WT AsCpf1, the 
RVR and RR variants efficiently recognize the TATV and TYCV PAMs, respectively. 
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3.5.3 Crystallization and X-ray diffraction analysis 
The RVR and RR variants in complex with a 43-nt crRNA containing 24-nt guide 
sequence, a 34-nt target DNA strand, and a 10-nt non-target DNA strand was 
crystallized under the condition A (Figures 3-5 and 3-6). The 2.0 Å resolution data sets 
were collected from both crystals. 
 
3.5.4 Phase determination, model building and structure refinement 
Molecular replacement was performed using the crystal structure of AsCpf1–crRNA–
target DNA complex as the search model, and thus interpretable electron density maps 
were obtained. The final structures were refined using the data sets respectively (RVR: 
2.0 Å resolution, Rwork/Rfree = 0.175/0.210, RR: 2.0 Å resolution, Rwork/Rfree = 
0.183/0.214) (Figures 3-7 and 3-8). Data collection and refinement statistics are shown 
in Table 3-1. 
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Table 3-1 Data collection and refinement statistics. 
 
RVR (TATA PAM) RR (TCCA PAM) 
Data collection 
 
 
Beamline SPring-8 BL41XU SPring-8 BL41XU 
Wavelength (Å) 1.0000 1.0000 
Space group P212121 P212121 
Cell dimensions   
 
 
a, b, c (Å) 81.2, 133.7, 199.6 80.7, 133.3, 200.0 
a, b, g  (°) 90, 90, 90 90, 90, 90 
Resolution (Å)* 40.0–2.0 (2.03–2.00) 40.0–2.0 (2.03–2.00) 
Rpim 0.021 (0.396) 0.034 (0.466) 
I/sI 17.1 (2.0) 10.5 (1.5) 
Completeness (%) 98.2 (98.3) 99.9 (99.9) 
Multiplicity 6.6 (6.6) 6.4 (6.4) 
CC(1/2) 0.999 (0.813) 0.999 (0.841) 
  
 
Refinement 
 
 
Resolution (Å) 
40.0–2.0 
(2.02–2.00) 
40.0–2.0 
(2.02–2.00) 
No. reflections 145,851 (4,771) 145,319 (4,787) 
Rwork / Rfree 
0.175 / 0.210 
(0.272 / 0.333) 
0183 / 0.214 
(0.256 / 0.304) 
No. atoms 
 
 
    Protein 10,455 10,431 
    Nucleic acid 1,639 1,639 
    Ion 6 6 
    Solvent 731 747 
B-factors (Å2) 
 
 
    Protein 51.8 49.5 
    Nucleic acid 50.2 48.2 
    Ion 50.1 45.2 
    Solvent 52.3 49.6 
R.m.s. deviations 
 
 
    Bond lengths (Å) 0.007 0.006 
    Bond angles (º) 0.843 0.834 
Ramachandran plot (%) 
 
 
    Favored region 98.27 98.12 
    Allowed region 1.65 1.80 
    Outlier region 0.08 0.08 
MolProbity score   
    Clashscore 2.68 2.48 
    Rotamer outlier 2.20 2.30 
*Values in parentheses are for the highest resolution shell. 
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3.5.5 Crystal structures of the AsCpf1 variants 
To elucidate the altered PAM recognition mechanisms of the AsCpf1 variants, we 
determined the crystal structures of (1) the RVR variant bound to the crRNA and its 
target DNA with the TATA PAM at 2.0 Å resolution, and (2) the RR variant bound to 
the crRNA and its target DNA with the TCCA PAM at 2.0 Å resolution (Figures 3-9 
and Table 3-1). The overall structures of the RVR and RR variants are essentially 
identical to that of WT AsCpf1 (Yamano et al., 2016) (root-mean-square deviations are 
0.53/0.60 Å for the equivalent Cα atoms between WT AsCpf1 and the RVR/RR 
variants) (Figure 3-9C). The AsCpf1 variants adopt a bilobed architecture consisting of 
a recognition (REC) lobe and a nuclease (NUC) lobe, in which the crRNA–target DNA 
heteroduplex is bound to the central channel between the two lobes (Figure 3-9C). In 
the two structures, the target DNA strand (nucleotides −10 to −1) and the 
PAM-containing non-target DNA strand (nucleotides −10* to −1*) form the PAM 
duplex, which is bound to the narrow channel formed by the WED, REC1 and PI 
domains (Figure 3-9C). The S542R/K548V/N552R and K607R substitutions, 
identified by random mutagenesis screening for 60 amino acid residues around the 
PAM duplex, are located in the WED and PI domains, respectively (Figures 3-10). 
Lys548 and Lys607 are conserved among the Cpf1 family proteins, and participate in 
the PAM recognition in the WT AsCpf1 structure (Yamano et al., 2016) (Figure 
3-10B). In contrast, Ser542 and Asn552 are not well conserved, and do not directly 
contact the PAM duplex in the WT AsCpf1 structure. 
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3.5.6 TTTA PAM recognition by WT AsCpf1 
In the WT AsCpf1 structure with the TTTA PAM, the PAM DNA duplex adopts a 
distorted conformation with a narrow minor groove, and is recognized by the WED, 
REC1 and PI domains (Yamano et al., 2016) (Figures 3-11A and 3-11B). Notably, the 
conserved Lys607 residue in the PI domain forms multiple interactions with the PAM 
duplex from the minor groove side. Lys607 forms hydrogen bonds with the O4ʹ′ of 
dA(−4), the N3 of dA(−3) and the O2 of dT(−2*) (Figures 3-11A and 3-11B). 
Moreover, Lys548 in the WED domain hydrogen bonds with the N7 of dA(−3) from 
the major groove side (Figure 3-11A). In the WT AsCpf1 structure, the 
dT(−1):dA(−1*) base pair does not form base-specific contacts with the AsCpf1 
protein (Yamano et al., 2016); nonetheless, our in vitro cleavage data and previous 
studies (Zetsche et al., 2015a; Kim et al., 2016b; Gao et al., 2016a) showed that 
AsCpf1 prefers the V (V is A, G or C) nucleotides at the fourth PAM position (Figures 
3-2C and 3-3C). To clarify structural basis for the fourth V preference, we modeled a 
T nucleotide at the fourth PAM position (dT(−1*)) in the WT AsCpf1 structure. The 
modeling indicated that the fourth PAM nucleotide adopts a distinct conformation, due 
to the interaction with the PI domain (Figure 3-11C), and that the 5-methyl group of 
dT(−1*) in the non-target strand is located closer (4.4 Å) to the neighboring backbone 
phosphate group, as compared with those of dT(−2*) (5.3 Å), dT(−3*) (5.7 Å) and 
dT(−4*) (5.3 Å) (Figure 3-11D). In addition, the modeling indicated that the dA(−1) in 
the target strand does not form unfavorable interactions with the protein. These 
observations suggested that AsCpf1 disfavors the fourth T in the PAM, likely due to 
the relatively shorter distance between its 5-methyl group and the backbone phosphate 
group. 
 
3.5.7 TATA PAM recognition by the RVR variant 
In the RVR (S542R/K548V/N552R) variant structure with the TATA PAM, the O4 of 
dT(−4*) forms a water-mediated hydrogen bond with Arg552 (N552R) (Figure 3-12A), 
explaining the preference for the first T in the TATV PAM. The N6 and N7 of 
dA(−3*) are recognized by Thr167 and Thr539 via a water-mediated 
hydrogen-bonding network (Figure 3-12A). Notably, the PAM-complementary dT(−3) 
is extensively recognized by the protein (Figures 3-12A, 3-12C and 3-12D). The O2 
and O4 of dT(−3) form hydrogen bonds with Lys607 and Arg552 (N552R), 
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respectively. In addition, the 5-methyl group of dT(−3) forms a hydrophobic 
interaction with the side chain of Val548 (K548V) (Figure 3-12C). These structural 
findings can explain the strong preference of the second A for the TATV PAM 
recognition by the RVR variant. As in the WT AsCpf1 structure, the O2 of dT(−2*) 
hydrogen bonds with Lys607 (Figure 3-12D). In addition, the N7 of dA(−2) hydrogen 
bonds with Arg552 (N552R) (Figures 3-12B and 3-12D). These structural observations 
are consistent with the preference for the third T in the TATV PAM. In the RVR 
variant, Arg542 (S542R) does not contact the PAM duplex. Together, these structural 
findings explain the mechanism of TATV PAM recognition by the RVR variant. 
 
3.5.8 TCCA PAM recognition by the RR variant 
In the RR (S542R/K607R) variant structure with the TCCA PAM, the O4 of dT(−4*) 
forms a water-mediated hydrogen bond with Lys548, while the N3 of dA(−4) 
hydrogen bonds with Arg607 (K607R) (Figure 3-13A). These observations explain the 
preference of the RR variant for the first T in the TYCV PAM. It is likely that, in WT 
AsCpf1, Lys548 forms a similar water-mediated interaction with dT(−4*) and 
contributes to the preference for the first T in the TTTV PAM, although such a water 
molecule was not resolved in the previous WT AsCpf1 structure at a lower resolution 
(2.8 Å) (Yamano et al., 2016). dC(−3*) does not directly contact the protein. Instead, 
the O6 and N7 of dG(−3) hydrogen bond with Lys548, while the N3 of dG(−3) forms a 
water-mediated hydrogen bond with Arg607 (K607R) (Figure 3-13A). It is likely that 
the N3 and N7 of the A nucleotide at this position are recognized by Arg607 (K607R) 
and Lys548, respectively. These observations explain the preference of the second Y 
for the TYCV PAM recognition by the RR variant. Notably, the O6 and N7 of dG(−2) 
are recognized by Arg542 (S542R) via bidentate hydrogen-bonding interactions, 
whereas dC(−2*) does not directly contact the protein (Figures 3-13B and 3-13C). 
These structural findings can explain the strong preference of the third C in the TYCV 
PAM recognition by the RR variant. Moreover, the side chain of Arg607 (K607R) 
inserts into the minor groove of the PAM duplex, and interacts with the ribose moieties 
of dA(−4), dC(−2*) and dA(−1*) (Figure 3-13D). Together, these structural findings 
explain the mechanism of TYCV PAM recognition by the RR variant. 
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3.5.9 Conformational differences in the PAM duplex 
A structural comparison between WT AsCpf1 and the variants revealed the 
conformational differences in their PAM duplexes (Figure 3-14). In the WT AsCpf1 
structure with the TTTA PAM, the PAM duplex adopts a distorted conformation 
characteristic of a T-rich DNA duplex, in which Lys607 forms multiple interactions 
with the minor-groove edge of the PAM duplex (Yamano et al., 2016) (Figure 3-14). 
In contrast, in the structures of the RVR (with the TATA PAM) and RR (with the 
TCCA PAM) variants, the PAM duplexes adopt B-form-like conformations (Figure 
3-14), supporting the notion that the distorted conformation of the PAM duplex in the 
WT AsCpf1 structure is due to the three successive T nucleotides. Unlike the RR 
variant, the RVR variant efficiently recognizes the TTTV PAM (Figures 3-2C and 
3-3C), and the location of the Lys607 residue is similar to that in the WT AsCpf1 
structure (Figure 3-14). These observations suggested that the RVR variant recognizes 
the TTTV PAM in a similar manner to that of WT AsCpf1, and highlighted the 
importance of Lys607 for the TTTV PAM recognition. 
 
3.5.10 Cooperative structural rearrangements induced by the substitutions 
A structural comparison between WT AsCpf1 and the two variants also revealed 
conformational differences in the AsCpf1 proteins. In the structures of the RVR and 
RR variants, Arg542 (S542R) adopts distinct conformations and plays different 
functional roles (Figure 3-15A). In the RR variant structure, Arg542 forms bidentate 
hydrogen bonds with dG(−2) in the target DNA strand, and plays a critical role in the 
TYCV PAM recognition (Figure 3-15A). In contrast, in the RVR variant structure, 
Arg542 in the WED domain interacts with Thr167 and Ser170 in the REC1 domain 
(Figure 3-15A). Our in vitro cleavage experiments revealed that the VR 
(K548V/N552R) variant exhibits reduced activities, as compared with the RVR 
(S542R/K548V/N552R) variant (Figure 3-16), indicating the functional importance of 
the Arg542-mediated inter-domain interaction. Given that Arg542 is located far away 
from the PAM duplex in the RVR structure, it is likely that Arg542 does not interact 
directly with the PAM duplex and contributes to the structural maintenance of the 
PAM-duplex channel, thereby enhancing the PAM recognition. 
 
Our high-resolution structures further revealed unexpected conformational 
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rearrangements induced by the N552R substitution in the RVR variant (Figure 3-15B). 
In the structures of WT AsCpf1 and the RR variant, the side chain of Asn552 hydrogen 
bonds with the side chain of Thr539 (Figure 3-15B). In the RR variant structure, the 
side chain of Asn552 also interacts with the backbone phosphate group between 
dA(−2) and dT(−1) (Figure 3-15B). In contrast, in the RVR variant structure, the side 
chains of Thr539 and Asn551 adopt distinct conformations, as compared with those in 
the WT AsCpf1 and RR variant structures, and interact with the side chain of Arg552 
(N552R) (Figure 3-15B). Arg552 (N552R) forms a water-mediated interaction with 
the backbone phosphate group between dA(−2) and dT(−1), while Asn551 interacts 
with the backbone phosphate group between dC(−6*) and dC(−5*). 
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3.6 Discussion 
The present high-resolution structures reveal the altered PAM recognition mechanisms 
of the RVR and RR variants, and also provide detailed insights into the functional 
mechanism of WT AsCpf1. WT AsCpf1 recognizes the TTTV PAM mainly via 
multiple interactions between Lys607 and the minor-groove edge of the PAM duplex 
(Yamano et al., 2016). In contrast, the RVR and RR variants achieve the altered PAM 
recognition via newly formed interactions with the major-groove edges of the 
PAM-complementary nucleotides in the target strand, rather than the altered PAM 
nucleotides in the non-target strand. In the RVR variant, Val548 (K548V) and Arg552 
(N552R) form base-specific contacts with the T nucleotide complementary to the 
altered second A in the TATV PAM. In the RR variant, Arg542 (S542R) forms 
bidentate hydrogen bonds with the G nucleotide complementary to the altered third C 
nucleotide in the TYCV PAM. This Arg–G interaction is frequently observed in 
Cas9-mediated PAM recognition, such as those in SpCas9 (Arg1333–G2 and 
Arg1335–G3 in the NGG PAM) (Anders et al., 2014), SaCas9 (Arg1015–G3 in the 
NNGRRT PAM) (Nishimasu et al., 2015) and Francisella novicida Cas9 (Arg1585–
G2 and Arg1556–G3 in the NGG PAM) (Hirano et al., 2016a). In addition, in the RR 
variant, Arg607 (K607R) donates hydrogen bonds and van der Waals contacts with the 
PAM duplex, thereby compensating for the loss of the interactions between Lys607 
and the PAM duplex observed in WT AsCpf1. 
 
A structural comparison of the AsCpf1 variants with the previously reported SpCas9 
variants, such as VQR (D1135V/R1335Q/T1337R) and VRER 
(D1135V/G1218R/R1335E/T1337R) (Kleinstiver et al., 2015), reveal striking 
differences in their altered PAM recognition mechanisms. Whereas the third G in the 
NGG PAM is recognized by Arg1335 in WT SpCas9 (Anders et al., 2014), the third A 
in the NGA PAM and the third C in the NGCG PAM are recognized by Gln1335 
(R1335Q) in the VQR variant and Glu1335 (R1335E) in the VRER variant, 
respectively (Anders et al., 2016; Hirano et al., 2016b). Thus, the altered PAM 
recognition by the SpCas9 variants mainly relies on the replacement of the Arg1335–
G3 interaction in WT SpCas9 with the altered base-specific interactions (i.e., the 
Gln1335–A3 interaction in the VQR variant and the Glu1335–C3 interaction in the 
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VRER variant). In contrast, the altered PAM recognition by the AsCpf1 variants relies 
on newly formed interactions between the substituted residues and the altered 
PAM-complementary nucleotides (i.e., Val548/Arg552–A2-complementary T2 in the 
RVR variant and Arg542–C3-complementary G3 in the RR variant). These differences 
are reflected by the distinct PAM recognition mechanisms of SpCas9 (base readout 
from the major-groove side) (Anders et al., 2014) and AsCpf1 (base and shape readout 
from the minor- and major-groove sides) (Yamano et al., 2016). 
 
The present structures reveals that Arg542 (S542R) plays distinct roles in the RVR and 
RR variants. Arg542 forms the inter-domain interactions and may reinforce the 
PAM-duplex binding channel in the RVR variant, whereas Arg542 forms the 
base-specific contacts with the PAM duplex in the RR variant. These observations 
demonstrate that the amino-acid substitutions that do not provide interactions with the 
PAM duplex can contribute to the engineering of the Cpf1’s PAM specificity. This 
contrasts with the altered PAM recognition by the SpCas9 variants, in which the 
substituted residues provide new contacts with the PAM duplex. These differences also 
highlight the mechanistic differences in the PAM recognition between SpCas9 (via the 
PAM-binding groove within the PI domain) (Anders et al., 2014) and AsCpf1 (via the 
PAM-binding channel formed by the WED, REC1 and PI domains) (Yamano et al., 
2016). Furthermore, the present findings provide important clues for the Cpf1 
engineering, and suggest that amino-acid substitutions that reinforce the PAM-binding 
channel could contribute to the alteration of the Cpf1’s PAM specificity. 
 
There are also mechanistic similarities in the altered PAM recognition by the SpCas9 
and AsCpf1 variants. In the SpCas9 and AsCpf1 variants, unexpected structural 
rearrangements play important roles in the altered PAM recognition, thus highlighting 
the power of structure-guided random mutagenesis approaches. In the SpCas9 variant 
structures, the direct hydrogen-bonding interactions between the altered third PAM 
nucleotides and the substituted residues (Gln1335 and Glu1335) are enabled by the 
unexpected displacement of the PAM duplex, which is cooperatively induced by the 
other substitutions (D1135V and T1337R) (Anders et al., 2016; Hirano et al., 2016b). 
In the AsCpf1 RR variant structure, the PAM duplex undergoes a conformational 
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change, partly due to the replacement of Lys607 (K607R). Moreover, in the AsCpf1 
RVR variant structure, the N552R substitution induces local conformational changes 
in Thr539 and Asn551, thus rearranging the interactions with the PAM duplex. These 
cooperative structural rearrangements are not readily predictable from the WT AsCpf1 
structure (Yamano et al., 2016), and thus confirm the power of the combination of 
structural information and molecular evolution for the engineering of the CRISPR-Cas 
nucleases. 
 
In summary, our structural studies reveal the altered PAM recognition mechanisms of 
the recently engineered AsCpf1 variants. Furthermore, the structural comparison 
between the AsCpf1 and SpCas9 variants enhance our understanding of the PAM 
recognition mechanisms of class 2 CRISPR-Cas nucleases, and provide a framework 
for the future engineering of the CRISPR-Cpf1 toolbox. 
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Chapter 4: Structural basis for the canonical 
and non-canonical PAM recognition by 
CRISPR-Cpf1 
 
4.1 Summary 
The RNA-guided Cpf1 (also known as Cas12a) nuclease associates with a CRISPR 
RNA (crRNA), and cleaves the double-stranded DNA target complementary to the 
crRNA guide. The two Cpf1 orthologs from Acidaminococcus sp. (AsCpf1) and 
Lachnospiraceae bacterium (LbCpf1) have been harnessed for eukaryotic genome 
editing. Cpf1 requires a specific nucleotide sequence, called a protospacer adjacent 
motif (PAM), for the target recognition. Besides the canonical TTTV PAM, Cpf1 
recognizes suboptimal C-containing PAMs. Here, we report four crystal structures of 
LbCpf1 in complex with the crRNA and its target DNA, containing either TTTA, 
TCTA, TCCA or CCCA as the PAM. These structures revealed that, depending on the 
PAM sequences, LbCpf1 undergoes conformational changes to form altered 
interactions with the PAM-containing DNA duplexes, thereby achieving the relaxed 
PAM recognition. Collectively, the present structures improve our mechanistic 
understanding of the PAM-dependent crRNA-guided DNA cleavage by the Cpf1 
family nucleases. 
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4.2 Introduction 
AsCpf1 and Lbpf1 were identified and biochemically characterized, and they have 
been harnessed for genome editing in eukaryotic cells (Hur et al., 2016; Kim et al., 
2016a, 2016b, 2016c; Kleinstiver et al., 2016b; Tang et al., 2017; Zetsche et al., 2015a, 
2016). AsCpf1 and LbCpf1 share 34% sequence identity, while they lack similarity 
with Cas9 outside their RuvC domains. Previous structural studies provided 
mechanistic insights into the crRNA–guided DNA recognition and cleavage by the 
Cpf1 family nucleases (Dong et al., 2016; Yamano et al., 2016; Gao et al., 2016). The 
crystal structures of the LbCpf1–crRNA binary complex (Dong et al., 2016) and the 
AsCpf1–crRNA–target DNA ternary complex (Yamano et al., 2016; Gao et al., 2016) 
revealed the bilobed architectures of Cpf1 and the crRNA recognition mechanism. The 
AsCpf1–crRNA–DNA structures further revealed the crRNA–guided DNA targeting 
and the PAM recognition mechanisms (Yamano et al., 2016; Gao et al., 2016). In 
addition, these structures identified the Nuc domain next to the RuvC nuclease domain, 
and biochemical data demonstrated that the Nuc domain is involved in the cleavage of 
the target DNA strand (Yamano et al., 2016). Moreover, a structural comparison 
between apo-LbCpf1 and the LbCpf1–crRNA complex indicated the crRNA-induced 
structural rearrangements in Cpf1 (Dong et al., 2016), and a structural comparison 
between the AsCpf1–crRNA–DNA ternary complex (Yamano et al., 2016; Gao et al., 
2016b) and the LbCpf1–crRNA binary complex (Dong et al., 2016) indicated a 
structural rearrangement accompanying the crRNA–target DNA heteroduplex 
formation. 
 
Previous in vitro cleavage experiments suggested that, whereas LbCpf1 and AsCpf1 
prefer the TTTV PAM, they also recognize C-containing sequences as suboptimal 
PAMs (Zetsche et al., 2015a). Indeed, a recent study demonstrated that LbCpf1 and 
AsCpf1 can modify target sites with the non-canonical C-containing PAMs, such as 
CTTA, TCTA and TTCA, in mammalian cells, albeit with lower efficiencies than 
those with the canonical TTTV PAM (Kim et al., 2016b). However, the mechanism by 
which Cpf1 recognizes both the canonical and non-canonical PAMs has remained 
elusive. Moreover, the mechanism of PAM recognition by LbCpf1 also remains 
unknown, due to the lack of structural information about the LbCpf1–crRNA–DNA 
complex. 
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4.3 Research aims 
In this study, we present that AsCpf1 and LbCpf1 can recognize both the canonical 
and non-canonical PAMs in vitro and in vivo. To explain the PAM preferences of Cpf1, 
we determined four crystal structures of LbCpf1 in complex with the crRNA and its 
target DNA, containing either TTTA, TCTA, TCCA or CCCA as the PAM, at 2.4–2.5 
Å resolutions. These structures revealed that LbCpf1 undergoes conformational 
changes to form distinct interactions with the PAM-containing DNA duplex, 
depending on the PAM sequences. A structural comparison of the LbCpf1–crRNA–
DNA ternary complex with the LbCpf1–crRNA binary complex revealed the 
conformational rearrangements in the protein upon the crRNA–target DNA 
heteroduplex formation. In addition, a structural comparison between LbCpf1 and 
AsCpf1 revealed similarities and differences in their crRNA–guided DNA cleavage 
mechanisms. Furthermore, a structural comparison of Cpf1 with Cas9 highlighted the 
fundamental differences in the PAM recognition mechanisms of the two class 2 
effector nucleases. 
 
 
4.4 Materials and methods 
4.4.1 Sample preparation 
The sample preparation was performed as previously described (Yamano et al., 2016), 
with minor modifications. The gene encoding full-length LbCpf1 (residues 1–1,226) 
was PCR-amplified using the pcDNA3.1-LbCpf1 plasmid (Zetsche et al. 2015) as the 
template, and cloned between the NdeI and XhoI sites of the modified pE-SUMO 
vector (LifeSensors). The mutations (D832A, E925A, D1180A and R1138A) were 
introduced by a PCR-based method. The plasmid DNAs were amplified in Escherichia 
coli Mach (Thermo Fisher Scientific), cultured in LB medium (Nacalai Tesque) at 
37°C overnight.  
The LbCpf1-expressing E. coli Rosetta2 (DE3) cells were cultured at 37°C in LB 
medium (containing 20 mg/l kanamycin) until the OD600 reached 0.8, and protein 
expression was then induced by the addition of 0.1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG) (Nacalai Tesque). The E. coli cells were 
further cultured at 20°C for 18 h, and harvested by centrifugation at 5,000 g for 10 min. 
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The E. coli cells were resuspended in buffer A (50 mM Tris-HCl, pH 8.0, 20 mM 
imidazole, 300 mM NaCl and 3 mM 2-mercaptoethanol), lysed by sonication, and then 
centrifuged at 40,000 g for 30 min. The supernatant was mixed with 5 ml Ni-NTA 
Superflow (QIAGEN) equilibrated with buffer A for about 1 hour at 4°C, and the 
mixture was loaded into an Econo-Column (Bio-Rad). The resin was washed with 5 
column volumes of buffer A, 5 column volumes of buffer B (50 mM Tris-HCl, pH 8.0, 
20 mM imidazole, 1 M NaCl and 3 mM 2-mercaptoethanol) and 3 column volumes of 
buffer A. The protein was eluted with buffer C (50 mM Tris-HCl, pH 8.0, 300 mM 
imidazole, 300 mM NaCl and 3 mM 2-mercaptoethanol). The protein was loaded onto 
a HiTrap SP HP column (GE Healthcare) equilibrated with buffer D (20 mM Tris-HCl, 
pH 8.0 and 200 mM NaCl). The column was washed with buffer D, and the protein 
was then eluted with a linear gradient of 200–1,000 mM NaCl. To remove the 
His6-SUMO-tag, the eluted protein was mixed with TEV protease (home made), and 
was dialyzed at 4°C for 12 h against buffer E (20 mM Tris-HCl, pH 8.0, 40 mM 
imidazole, 300 mM NaCl and 3 mM 2-mercaptoethanol). The protein was passed 
through the Ni-NTA column equilibrated with buffer E. The protein was concentrated 
using an Amicon Ultra 10K filter (Millipore), and was further purified by a HiLoad 
Superdex 200 16/60 column (GE Healthcare) equilibrated with buffer F (10 mM 
Tris-HCl, pH 8.0, 150 mM NaCl and 1 mM DTT). The purified LbCpf1 proteins were 
stored at −80°C until use. The crRNA and target DNA were purchased from Gene 
Design and Sigma-Aldrich, respectively. The purified LbCpf1 protein was mixed with 
the crRNA, the target DNA strand and the non-target DNA strand (molar ratio, 
1:1.5:2.3:2.3), and the reconstituted complex was concentrated using an Amicon Ultra 
10K filter. The LbCpf1–crRNA–target DNA complex was purified by gel filtration 
chromatography on a Superdex 200 Increase column (GE Healthcare) equilibrated 
with buffer F. 
 
4.4.2 In vitro cleavage assay 
In vitro cleavage experiments were performed as previously described (Nishimasu et 
al., 2015), with minor modifications. The EcoRI-linearized pUC119 (100 ng, 4.7 nM), 
containing the 24-nt target sequence and the PAMs, was incubated with the Cpf1–
crRNA complex (50 nM) at 37°C for 5 min, in 20 µl of reaction buffer containing 20 
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mM HEPES-NaOH, pH 7.5, 100 mM KCl, 2 mM MgCl2, 1 mM DTT and 5% glycerol. 
The reaction was stopped by the addition of a solution containing EDTA (40 mM final 
concentration) and Proteinase K (10 µg). Reaction products were resolved on an 
ethidium bromide-stained 1% agarose gel, and then visualized using an Amersham 
Imager 600 (GE Healthcare). To examine the time course of DNA cleavage, the 
EcoRI-linearized pUC119 target (600 ng, 4.7 nM) was incubated with the Cpf1–
crRNA complex (50 nM) at 37°C in 60 µl reaction buffer. Aliquots (10 µl) were taken 
at the indicated time points, and the reaction products were then analyzed as described 
above. To examine whether Cpf1 serves as a nickase, the circular pUC119 target (100 
ng, 4.7 nM) was incubated with the Cpf1–crRNA complex (100 nM) at 37°C for 20 
min in 10 µl reaction buffer, and the reaction products were then analyzed as described 
above. In vitro cleavage experiments were performed at least three times, and 
representative results are shown. 
 
4.4.3 In vivo cleavage assay 
This experiment was performed partly in collaboration with Dr. Feng Zhang (MIT). 
Human embryonic kidney 293T (HEK) cells were maintained in Dulbecco’s modified 
Eagle medium (Gibco), supplemented with 10% fetal bovine serum (FBS), at 37°C 
under a 5% CO2 atmosphere. HEK cells were seeded at 1.25 × 105 cells per well in 
24-well plates, 24 h prior to transfection. Plasmids encoding humanized LbCpf1 
(pY027) or AsCpf1 (pY026) with C-terminal nuclear localization tags and U6-driven 
crRNAs were transfected at 500 ng per well, using the Lipofectamine 2000 reagent 
(Life Technologies). Genomic DNA was extracted using 100 µl QuickExtract DNA 
Extraction Solution (Epicenter), 3 days post-transfection. Insertion/deletion events 
(indels) were analyzed by a Surveyor nuclease assay, as previously described (Ran et 
al., 2013). Briefly, the genomic regions flanking the target sites for DNMT1 or EMX1 
were PCR-amplified, and the products were purified using a QIAQuick PCR 
purification Kit (QIAGEN) according to the manufacturer’s protocol. The purified 
PCR products (200 ng) were mixed with 1 µl 10 × Taq DNA Polymerase PCR buffer 
(Enzymatics) and ultrapure water to a final volume of 10 µl, and subjected to a 
re-annealing process to enable heteroduplex formation: 95°C for 10 min, 95°C to 85°C 
ramping at −2°C/s, 85°C to 25°C at −0.25°C/s, and 25°C hold for 1 min. After 
re-annealing, the products were treated with Surveyor nuclease and Surveyor enhancer 
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S (IDT), according to the manufacturer’s recommended protocol, and analyzed on 10% 
Novex TBE polyacrylamide gels (Life Technologies). The gels were stained with 
SYBR Gold DNA stain (Life Technologies) for 10 min, and imaged with a Gel Doc 
gel imaging system (Bio-Rad). Quantification was based on the relative band 
intensities. The indel percentage was determined by the formula, 100 × (1 − (1 − (b + 
c)/(a + b + c))1/2), where a is the integrated intensity of the undigested PCR product, 
and b and c are the integrated intensities of each cleavage product. In vivo cleavage 
experiments were performed at three times, and data are shown as mean ± s.e.m (n = 
3). 
 
4.4.4 Crystallization 
Two crRNAs with different length of the guide sequences (20-nt or 24-nt) were 
designed based on the previous study. The crRNAs were purchased from Gene Design. 
PAM containing target DNAs were designed to partially form the PAM duplex. The 
length of PAM duplex is predicted to affect the crystallization of the complex, so five 
target DNAs with different length of the duplex were prepared (7-bp, 8-bp, 9-bp, 10-bp, 
or 11-bp). The target and non-target DNA strands were purchased from Sigma-Aldrich. 
The peak fractions of the purified LbCpf1–crRNA–target DNA complex were 
concentrated by Amicon Ultra 10K filter. Using the concentrated complex solution 
(A260 nm = 10), the initial crystallization screening was performed at 20°C by the 
sitting-drop vapor diffusion method. 
 
The screening kits used for the initial screening 
Crystal Screen, PEG/Ion (Hampton Research) 
JBScreen Classic 1, 2, 4, 5 (Jena Bioscience) 
MemGold, MemGold2, JCSG-plus, PACT premier (Molecular Dimensions) 
Wizard Classic 1 and 2 (Emerald Biosystems) 
 
For crystallization optimization, Additive Screen (Hampton Research) was added to 
the reservoir solutions, in addition to the optimization of the concentration of 
precipitations and salt, and pH of the buffers. After the optimization by the sitting-drop 
vapor diffusion method, further optimization was performed by the hanging-drop 
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vapor diffusion method. The crystallization drops were formed by mixing 1 µl of 
complex solution (A260 nm = 10) and 1 µl of reservoir solution (13–18% PEG3,350 and 
100 mM MIB buffer, pH 5.0), and then were incubated against 0.5 ml of reservoir 
solution. The crystals were improved by micro-seeding using Seed Bead (Hampton 
Research). In the sitting-drop vapor diffusion method, the crystallization conditions 
were prepared using PLATEMASTER P220 (GILSON) and Mosquito crystallization 
robot (TTP Labtech). 
 
4.4.5 X-ray diffraction analysis and data processing 
The crystals of the TCTA, TCCA and CCCA complexes were cryoprotected in a 
solution consisting of 16–20% PEG3,350, 100 mM MIB buffer, pH 5.0, and 30% 
ethylene glycol. The crystals of the TTTA PAM complex were cryoprotected in the 
solution supplemented with 50 mM MgCl2. To reduce radiation damage, all 
X-ray-diffraction data were collected at 100 K on the beamline BL41XU at SPring-8, 
and PXI at the Swiss Light Source. A diffraction data set was collected from a single 
crystal using a X-ray beam at a wavelength of 1.000 Å, an oscillation range of 120° 
(0.1° per image), an exposure time of 1.0 s per image. The diffraction data were 
processed using DIALS (Waterman et al., 2013) and AIMLESS (Evans and 
Murshudov, 2013). 
 
4.4.6 Phase determination, model building and structure refinement 
The TTTA complex structure was determined by molecular replacement with Molrep 
(Vagin and Teplyakov, 2010), using the coordinates of LbCpf1 (PDB: 5ID6) (Dong et 
al., 2016) as the search model. The TCTA, TCCA and CCCA complex structures were 
determined by molecular replacement, using the TTTA complex structure as the search 
model. The model building and structural refinement were performed using COOT 
(Emsley and Cowtan, 2004) and PHENIX (Adams et al., 2010), respectively. 
Structural figures were prepared using CueMol (http://www.cuemol.org). 
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4.5 Results 
4.5.1 Sample preparation 
WT LbCpf1 protein was stable and the expression level was high. Furthermore, WT 
LbCpf1 was highly purified by the combination of the Ni-NTA chromatography, the 
cation exchange chromatography, and the gel filtration chromatography. The gel 
filtration chromatogram peak showed monodispersity (Figures 4-1). The final yield of 
the WT LbCpf1 was 14.2 mg per 1 L culture medium. 
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4.5.2 DNA cleavage activities of LbCpf1 and AsCpf1 
The in vitro DNA cleavage activities of purified LbCp1 and AsCpf1 have not been 
fully investigated, although their activities were compared in mammalian cells (Kim et 
al., 2016a; Kleinstiver et al., 2016b) and plant cells (Tang et al., 2017). We thus 
measured the in vitro DNA cleavage activities of purified LbCpf1 and AsCpf1, using a 
plasmid DNA substrate with a 24-nt target sequence and the TTTA PAM (Figure 
4-2A). LbCpf1 cleaved the plasmid target slightly more efficiently than AsCpf1 
(Figure 4-2A). Previous studies indicated that, while LbCpf1 and AsCpf1 recognize 
TTTV (V is A, G or C) as the optimal PAM, they also recognize C-containing 
sequences, such as CTTV, TCTV and TTCV, as suboptimal PAMs (Kim et al., 2016b). 
To examine their preference for the fourth PAM nucleotide, we measured the cleavage 
activities of LbCpf1 and AsCpf1 toward four target sites, with either TTTA, TTTT, 
TTTG or TTTC as the potential PAM (Figure 4-2B). LbCpf1 and AsCpf1 efficiently 
cleaved the TTTA, TTTG and TTTC sites, but not the TTTT site (Figure 4-2B), 
confirming their preferences for the fourth V in the TTTV PAM. To further explore 
their PAM specificities, we measured their cleavage activities toward seven target sites 
with either TTTA, CTTA, TCTA, TTCA, CCTA, TCCA or CCCA as the potential 
PAM (Figure 4-2C). LbCpf1 and AsCpf1 cleaved the target sites with either CTTA, 
TCTA or TTCA as the PAM, albeit with lower efficiencies than the TTTA site (Figure 
4-2C). In contrast, LbCpf1 and AsCpf1 were less active toward the CCTA, TCCA and 
CCCA sites (Figure 4-2C). These results confirmed that LbCpf1 and AsCpf1 recognize 
CTTV, TCTV and TTCV as the suboptimal non-canonical PAMs. 
Furthermore, we examined the activities of LbCpf1 and AsCpf1 toward 42 endogenous 
target sites, with either TTTV, CTTV, TCTV, TTCV, CCTV, TCCV or CCCV as the 
potential PAM, in the DNMT1 and EMX1 loci in HEK293 cells (Figures 4-3). LbCpf1 
and AsCpf1 efficiently modified all six of the target sites with the canonical TTTV 
PAM (Figures 4-3). In contrast, LbCpf1/AsCpf1 modified the 4/3 CTTV, 3/4 TCTV, 
4/3 TTCV, 2/2CCTV, 3/2 TCCV and 1/0 CCCV sites, respectively (Figures 4-3). 
These results revealed that LbCpf1 and AsCpf1 can edit the endogenous sites with the 
CTTV, TCTV or TTCV PAM, consistent with our in vitro cleavage data and a recent 
in vivo study (Kim et al., 2016b). Together, these results confirmed that, in addition to 
the canonical TTTV PAM, LbCpf1 and AsCpf1 can target CTTV, TCTV and TTCV as 
suboptimal non-canonical PAMs. 
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4.5.3 Crystallization and X-ray diffraction analysis 
The WT LbCpf1 in complex with a 40-nt crRNA containing 20-nt guide sequence, a 
29-nt target DNA strand, and a 9-nt non-target DNA strand containing the TTTA PAM 
was suitable for crystallization. In the initial screening, the initial crystals of the 
complex were obtained under the conditions of No. 15 of PACT (25% PEG1,500, 100 
mM MIB buffer pH 6.0) by sitting-drop vapor diffusion method. As a result of the 
optimization of the condition, the crystals suitable for the X-ray diffraction analysis 
were obtained under the condition C (13–18% PEG3,350, 100 mM MIB buffer (pH 
5.0)) (Figure 4-4). The 2.5 Å resolution data sets of the TTTA complex were collected. 
Although the crystals of TTTA, TCTA, TCCA, and CCCA complexes were obtained 
under the same condition, the micro seeding was necessary to obtain the crystals of the 
TCTA, TCCA, and CCCA complexes (Figures 4-5). The data sets of the TCTA, 
TCCA, and CCCA complexes were collected in 2.4 Å, 2.5 Å and 2.4 Å resolutions, 
respectively.  
 
4.5.4 Phase determination, model building and structure refinement 
Molecular replacement was performed using the crystal structure of LbCpf1–crRNA 
binary complex as the search model, and thus interpretable electron density maps were 
obtained. The final structures were refined using the data sets respectively (TTTA: 2.5 
Å resolution, Rwork/Rfree = 0.178/0.228, TCTA: 2.4 Å resolution, Rwork/Rfree = 
0.193/0.238, TCCA: 2.5 Å resolution, Rwork/Rfree = 0.193/0.244, CCCA: 2.4 Å 
resolution, Rwork/Rfree = 0.178/0.229) (Figures 4-6 and 4-7). Data collection and 
refinement statistics are shown in Table 4-1. 
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Table 4-1 Data collection and refinement statistics. 
 
TTTA TCTA TCCA TCCC 
Data collection 
 
   
Beamline 
SLS 
PXI 
SPring-8 
BL41XU 
SPring-8 
BL41XU 
SLS 
PXI 
Wavelength (Å) 1.0000 1.0000 1.0000 1.0000 
Space group P41212 P41212 P41212 P212121 
Cell dimensions   
 
   
a, b, c (Å) 103.2, 103.2, 
363.9 
102.5, 102.5, 
373.9 
102.0, 102.0, 
372.5 
102.0, 103.5, 
342.7 
α, β, γ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å)* 
49.6–2.5 
(2.56–2.50) 
49.4–2.4 
(2.45–2.40) 
49.2–2.5 
(2.56–2.50) 
49.9–2.4 
(2.44–2.40) 
Rpim 0.033 (0.436) 0.014 (0.339) 0.024 (0.518) 0.043 (0.162) 
I/σI 12.7 (1.6) 25.0 (2.1) 15.6 (1.6) 9.2 (2.8) 
Completeness (%) 99.9 (100) 96.3 (97.8) 99.8 (100) 97.3 (82.8) 
Multiplicity 12.6 (12.7) 8.9 (7.0) 8.6 (9.0) 4.0 (3.4) 
CC(1/2) 0.997 (0.677) 0.999 (0.700) 0.998 (0.543) 0.993 (0.889) 
  
   
Refinement 
 
   
Resolution (Å) 
49.7–2.5 
(2.53–2.50) 
49.4–2.4 
(2.43–2.40) 
49.2–2.5 
(2.53–2.50) 
49.9–2.4 
(2.43–2.40) 
No. reflections 
69,046 
(2,583) 
75,435 
(2,649) 
69,014 
(2,617) 
138,080 
(3,632) 
Rwork / Rfree 
0.178 / 0.228 
(0.289 / 0.394) 
0.193 / 0.238 
(0.307 / 0.383) 
0.193 / 0.244 
(0.340 / 0.383) 
0.178 / 0.229 
(0.216 / 0.278) 
No. atoms 
 
   
Protein 9,776 9,794 9,749 19,707 
Nucleic acid 1,618 1,618 1,618 3,236 
Ion 5 2 2 5 
Solvent 143 53 27 471 
B-factors (Å2) 
 
   
Protein 83.4 81.6 88.8 60.5 
Nucleic acid 71.3 76.4 83.5 52.0 
Ion 75.7 77.9 79.2 38.8 
Solvent 66.8 60.1 68.8 46.2 
R.m.s. deviations 
 
   
Bond lengths (Å) 0.007 0.007 0.007 0.007 
Bond angles (°) 0.913 0.904 0.924 0.883 
Ramachandran plot (%)     
Favored region 96.83 95.62 95.94 96.56 
Allowed region 3.01 3.96 3.89 3.20 
Outlier region 0.17 0.41 0.17 0.25 
*Values in parentheses are for the highest resolution shell.   
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4.5.5 Overall structure of the LbCpf1–crRNA–target DNA complex 
To clarify the crRNA-guided DNA cleavage mechanism of LbCpf1, we determined the 
crystal structure of LbCpf1 (residues 1–1,226) in complex with a 40-nt crRNA, a 29-nt 
target DNA strand and a 9-nt non-target DNA strand containing the TTTA PAM, at 
2.5-Å resolution (Figures 4-6 and 4-8A–4-8D and Table 4-1). LbCpf1 adopts a bilobed 
architecture consisting of a recognition (REC) lobe and a nuclease (NUC) lobe (Figure 
4-8C). The REC lobe includes the REC1 and REC2 domains, whereas the NUC lobe 
comprises the Wedge (WED), PAM-interacting (PI), RuvC and Nuc domains. A 
characteristic α helix (referred to as the bridge helix) between the RuvC-I and RuvC-II 
regions interacts with the REC2 domain. The crRNA consists of the 20-nt 5ʹ′-handle 
and the 20-nt guide sequence (Figure 4-8D). The crRNA guide sequence and the target 
DNA strand form the 20-bp RNA–DNA heteroduplex, which is accommodated in the 
central channel between the two lobes (Figures 4-8C, 4-8D and 4-9). Two Mg2+ ions 
are bound to the crRNA 5ʹ′-handle (Figure 4-8E). One Mg2+ is coordinated by six water 
molecules that interact with the phosphate groups of A(−13), U(−14) and A(−19) and 
the nucleobases of A(−13) and U(−18), as observed in the LbCpf1–crRNA binary 
complex (Dong et al., 2016). The other Mg2+ is coordinated by the main-chain 
carbonyl group of Thr716, the phosphate group of A(−4) and four water molecules that 
interact with the phosphate groups of G(−3) and U(−5) and the side chains of Asp708 
and Asn718 (Figure 4-8E). 
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4.5.6 Structural rearrangement upon target DNA binding 
A structural comparison between the LbCpf1 binary and ternary complexes revealed 
that, while the individual domains are structurally similar, the REC1, REC2 and PI 
domains undergo conformational rearrangements upon target DNA binding (Figures 
4-10A, 4-10B and 4-11). These structural rearrangements are consistent with a 
previous prediction, based on a comparison of the LbCpf1 binary complex with the 
AsCpf1 ternary complex (Gao et al., 2016). As compared to the binary complex, the 
REC1 and REC2 domains move toward and away from the NUC lobe in the ternary 
complex, respectively, to form the central channel that accommodates the crRNA–
target DNA heteroduplex (Figures 4-10A, 4-10B and 4-11B). In the ternary complex, 
the PI domain moves toward the REC1 and WED domains to form the PAM-binding 
channel (Figures 4-10B and 4-11C). In addition, whereas the crRNA guide segment is 
disordered in the binary complex (Dong et al., 2016), the crRNA guide is ordered and 
forms the heteroduplex with the target DNA in the ternary complex (Figures 4-10B 
and 4-11D). 
 
A structural comparison between the binary and ternary complexes also revealed a 
local conformational change in the bridge helix and the RuvC-II region. In the binary 
complex, residues 872–885/890–918 and 886–889 adopt α-helical and loop 
conformations, respectively (Dong et al., 2016) (Figure 4-10C). In contrast, in the 
ternary complex, residues 885–889 and 890–896 adopt α-helical and loop 
conformations, respectively (Figure 4-10D). In the binary and ternary complexes, 
Trp890 is inserted into a hydrophobic pocket in the REC2 domain (Figures 4-10C and 
4-10D). In addition, in the ternary complex, the main-chain carbonyl group of Gln888 
hydrogen bonds with the side chain of Lys457 in the REC2 domain (Figure 4-10D). 
These interdomain interactions are conserved in the AsCpf1 ternary complex (Figure 
4-10E), and the W958A mutation reduced the DNA cleavage activity (Yamano et al., 
2016). These observations highlighted the pivotal role of the conserved tryptophan 
residue in the RuvC domain for the structural transition from the binary to the ternary 
complex. 
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4.5.7 RNA-DNA heteroduplex recognition mechanism 
A structural comparison between the ternary complexes of AsCpf1 and LbCpf1 
revealed that they share a bilobed architecture and recognize the RNA–DNA 
heteroduplex in similar manners (Figures 4-12A and 4-12B). In the LbCpf1 ternary 
complex, the 20-bp RNA–DNA heteroduplex is recognized by the REC lobe, in which 
Trp355 in the REC2 domain stacks with the C20:dG20 base pair in the heteroduplex 
(Figure 4-12C). Similarly, in the AsCpf1 ternary complex, the 20-bp heteroduplex is 
accommodated within the REC lobe, in which Trp382, equivalent to Trp355 in LbCpf1, 
stacks with the C20:dG20 base pair, while AsCpf1 was crystallized with a 
24-nt-guide-containing crRNA and its complementary target DNA (Yamano et al., 
2016) (Figure 4-12D). Consistent with these structural findings, the crRNA–DNA base 
pairing in the PAM-distal region is dispensable for the Cpf1-mediated DNA cleavage  
(Kim et al., 2016a, 2016b; Kleinstiver et al., 2016b; Zetsche et al., 2015a). Together, 
these observations indicated that LbCpf1 and AsCpf1 recognize the 20-bp crRNA–
target DNA heteroduplex. 
 
4.5.8 RuvC and Nuc domains 
The RuvC and Nuc domains of LbCpf1 are structurally similar to those of AsCpf1 
(Figures 4-12E and 4-12F). In the AsCpf1 structure, the RuvC active site is formed by 
the conserved acidic residues Asp908, Glu993 and Asp1263 (Yamano et al., 2016) 
(Figure 4-12F). The D908A, E993A and D1263A mutations abolished the in vitro 
cleavage activities, indicating that the RuvC domain is involved in the cleavage of 
both strands (Zetsche et al., 2015; Yamano et al., 2016). In contrast, Arg1226 in the 
Nuc domain participates in the target strand cleavage (Yamano et al., 2016). In the 
LbCpf1 structure, Asp832, Glu925, Asp1180 and Arg1138, equivalent to Asp908, 
Glu993, Asp1263 and Arg1226 of AsCpf1, are similarly arranged (Figures 4-12E and 
4-13). In addition, our in vitro cleavage assays confirmed that the D832A, E925A and 
D1180A mutations abolish the DNA cleavage activity of LbCpf1, while the R1138A 
mutant functions as a nickase, as in the case of AsCpf1 (Yamano et al., 2016; Zetsche 
et al., 2015a) (Figure 4-14). These observations indicated that LbCpf1 and AsCpf1 
cleave the target DNA via similar mechanisms, in which the RuvC domain participates 
in the cleavage of both strands, while the Nuc domain is involved in the target strand 
cleavage. 
 122 
 
Recently, the crystal structures of C2c1 (also known as Cas12b) from Alicyclobacillus 
acidoterrestris (AaC2c1), which was identified as a type V-B effector nuclease 
(Shmakov et al., 2015), elucidated its action mechanism and offered clues toward 
understanding the DNA cleavage mechanism of the type V-A Cpf1 nucleases (Liu et 
al., 2016; Yang et al., 2016). Despite their limited sequence similarity, Cpf1 and C2c1 
have comparable domain architectures and share the RuvC domain, in which the 
catalytic residues are similarly arranged (Figures 4-15A–4-15D). As in Cpf1, the Nuc 
domain is located next to the RuvC domain in C2c1, although their Nuc domains adopt 
distinct folds (Figures 4-15A and 4-15B). In the AaC2c1 structure, Arg911 in the Nuc 
domain interacts with the backbone phosphate group of the target strand, thereby 
guiding the target strand into the RuvC active site (Figure 4-15D). These structural 
observations suggested that C2c1 uses the RuvC active site to cleave both the target 
and non-target strands (Yang et al., 2016). Notably, LbCpf1 Arg1138 and AsCpf1 
Arg1226 are located at positions analogous to that of AaC2c1 Arg911 (Figures 4-15C 
and 4-15D), and they are involved in the target strand cleavage (Yamano et al., 2016) 
(Figure 4-14). Thus, these observations suggested that the Cpf1 Nuc domain plays a 
role in guiding the target strand into the RuvC active site, rather than catalyzing the 
cleavage of the target strand. Supporting this notion, a recent study indicated that 
Francisella novicida Cpf1 cleaves the target and non-target DNA strands, using the 
same RuvC domain active site (Swarts et al., 2017). 
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4.5.9 Recognition mechanism of the canonical TTTV PAM 
In the LbCpf1 ternary complex, the TTTA PAM duplex is bound to the channel 
formed by the REC1, WED and PI domains (Figures 4-16A and 4-16B). The PAM 
duplex adopts a distorted conformation with a narrow minor groove, as compared with 
the canonical B-form DNA (root-mean-square deviation (RMSD) is 1.4 Å for 18 
equivalent phosphorus atoms), as observed in the AsCpf1 ternary complex (Yamano et 
al., 2016) (Figure 4-16C). The dT(−1):dA(−1*) base pair in the PAM duplex does not 
form base-specific contacts with the protein (Figure 4-16B). The O2 of dT(−2*) forms 
a hydrogen bond with Lys595, whereas the N7 of dA(−2) and the backbone phosphate 
group between dT(−1) and dA(−2) form hydrogen bonds with Tyr542 (Figure 4-17A). 
dA(−2) also forms van der Waals interactions with Pro587, Met592 and Lys595. The 
5-methyl group of dT(−3*) is in the vicinity of the side-chain methyl group of Thr149, 
whereas the N3 and N7 of dA(−3) form hydrogen bonds with Lys595 and Lys538, 
respectively (Figure 4-17B). The 5-methyl group of dT(−4*) is surrounded by the side 
chains of Thr149 and Gln529, whereas the O4ʹ′ of dA(−4) forms a hydrogen bond with 
Lys595 (Figure 4-17C). 
 
A structural comparison of LbCpf1 with AsCpf1 revealed the high conservation 
between their PAM recognition mechanisms. In AsCpf1, Lys548 and Lys607, 
equivalent to Lys538 and Lys595 of LbCpf1, similarly interact with the PAM duplex 
(Yamano et al., 2016) (Figures 4-13 and 4-17D–4-17F). Nonetheless, their PAM 
recognition mechanisms are slightly different. Whereas Tyr542 of LbCpf1 forms two 
hydrogen bonds with dA(−2) (Figure 4-17A), Asn552 of AsCpf1, equivalent to Tyr542 
of LbCpf1, does not interact with the PAM duplex (Figure 4-17D). 
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4.5.10 Recognition mechanisms of the non-canonical PAMs 
To investigate the non-canonical PAM recognition mechanism, we determined the 
crystal structures of the LbCpf1 ternary complex containing either TCTA, TCCA or 
CCCA as the PAM (Table 4-1). As in the TTTA complex, the TCTA and TCCA 
complexes crystallized in the space group P41212, with one complex molecule in the 
asymmetric unit. In contrast, the CCCA complex crystallized in the space group 
P212121, with two complex molecules in the asymmetric unit, probably due to the 
slightly different conformations of the bound DNA molecules. Since the two CCCA 
complex molecules are essentially identical (RMSD is 1.3 Å for equivalent Cα atoms), 
we will refer to one complex molecule for the following discussion. 
 
In the three complexes, the PAM duplexes are recognized by the REC1, WED and PI 
domains, as in the TTTA complex (Figures 4-18A–4-18C), and they adopt less 
distorted conformations, as compared with that in the TTTA complex, probably due to 
the presence of the G:C base pair(s) (Figure 4-18D). A comparison of the four 
complex structures revealed that, whereas the REC1 and WED domains are similarly 
arranged, the PI domains undergo outward displacement in the TCTA, TCCA and 
CCCA complexes, as compared with that in the TTTA complex (Figures 4-18A–
4-18C). The RMSD values for the equivalent Cα atoms in the PI domain between the 
TTTA complex and the TCTA/TCCA/CCCA complexes are 2.2, 2.4 and 2.2 Å, 
respectively, by superimposition based on the regions except for the PI domain. The PI 
domain displacement results in the opening of the PAM-binding channel, thereby 
allowing the binding of PAM duplexes with distinct conformations. Consistent with its 
conformational flexibility, the PI domain exhibits higher B-factor values than the other 
domains in the four complexes (Figures 4-19A–4-19D). Furthermore, the PI domain in 
the TTTA complex displays lower B-factor values than those in the TCTA and TCCA 
complexes (Figures 4-19A–4-19C). These structural observations suggest that LbCpf1 
binds the TTTA PAM duplex more stably than the non-canonical PAM duplexes, 
thereby explaining the preference of LbCpf1 for the canonical TTTV PAM. 
 
In the four complex structures, Lys538 and Tyr542 similarly interact with the second 
and third PAM-complementary nucleotides (Figures 4-20). In contrast, Lys595 
interacts with the PAM nucleotides in distinct manners among the four complex 
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structures, due to the conformational differences in the PI domain and the PAM duplex 
(Figures 4-20E–4-20H). In the TTTA complex, Lys595 forms hydrogen bonds with the 
N3 of dA(−3) and the O2 of dT(−2*) (Figure 4-20E). In contrast, in the TCTA 
complex, Lys595 does not hydrogen bond with the N3 of dG(−3) (Figure 4-20F). 
Notably, in the TCCA and CCCA complexes, Lys595 is not inserted into the minor 
groove of the PAM duplex (Figures 4-20G and 4-20H), probably due to steric 
hindrance between Lys595 and the N2 of dG(−2) (Figure 4-19E). These structural 
observations are consistent with the fact that LbCpf1 recognizes the non-canonical 
C-containing PAMs less efficiently than the canonical TTTV PAM. In addition, the 
side chain of Lys595 is less ordered in the TCTA, TCCA and CCCA complexes, as 
compared with that in the TTTA complex (Figures 4-20A–4-20D), consistent with the 
weaker interactions between Lys595 and the non-canonical PAM duplexes. Given the 
highly conserved PAM recognition mechanisms, AsCpf1 likely recognizes the 
non-canonical PAMs in similar manners. Together, these structural findings revealed 
the previously undescribed mechanisms of the canonical and non-canonical PAM 
recognition by the Cpf1 nucleases. 
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4.6 Discussion 
In this study, we showed that LbCpf1 and AsCpf1 recognize TTTV and 
CTTV/TCTV/TTCV as the canonical and non-canonical PAMs, respectively, 
consistent with a recent study (Kim et al., 2016b). We further determined the LbCpf1–
crRNA–DNA structures with either the TTTA, TCTA, TCCA or CCCA PAM. A 
structural comparison of LbCpf1 with AsCpf1 highlighted the mechanistic similarities 
in the crRNA-guided DNA recognition and cleavage among the Cpf1 nucleases. The 
TTTA complex structure revealed that LbCpf1 recognizes the canonical TTTV PAM 
via the shape and base readout mechanism, in which Lys595 inserts into the minor 
groove of the PAM duplex. Lys607 of AsCpf1, equivalent to Lys595 of LbCpf1, forms 
similar interactions with the PAM duplex (Yamano et al., 2016), and these lysine 
residues are conserved among the Cpf1 family members (Zetsche et al., 2015a) (Figure 
4-13), suggesting that the Cpf1 orthologs recognize their T-rich PAMs in similar 
manners. Moreover, the present structures revealed that Lys595 is also important for 
the discrimination between the canonical and non-canonical PAMs. 
 
The present structures also highlighted the fundamental differences in the PAM 
recognition mechanisms between the type-II Cas9 and type-V Cpf1 effector nucleases 
(Figures 4-21). In Cas9, the PAM duplex is accommodated within the PAM-binding 
groove in the PI domain, in which the major-groove edges of the PAM nucleotides are 
recognized by distinct sets of PAM-interacting residues via hydrogen-bonding 
interactions (i.e., base readout mechanism) (Anders et al., 2014; Nishimasu et al., 
2015; Hirano et al., 2016; Yamada et al., 2017). A structural comparison between the 
binary and ternary complexes of Cas9 suggested that the PAM-binding groove is 
pre-organized for the PAM recognition (Nishimasu et al., 2014; Anders et al., 2014; 
Jiang et al., 2015) (Figure 4-21B). In contrast, in Cpf1, the PAM duplex is enveloped 
within the PAM-binding channel formed by the WED, REC1 and PI domains, in which 
both the sequence and conformation of the PAM duplex are primarily recognized by 
the two conserved lysine residues (LbCpf1 Lys538/Lys595 and AsCpf1 
Lys548/Lys607) (i.e., base and shape readout mechanism). Importantly, the present 
LbCpf1 structures revealed that, in contrast to the PAM-binding groove of Cas9, the 
PAM-binding channel of Cpf1 has conformational flexibility, which allows the 
recognition of the canonical and non-canonical PAMs (Figure 4-21A). 
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The tolerant PAM recognition of Cpf1 is unfavorable for the gene editing, and it 
makes difficult to select target sites and design guide RNAs. However, it may confer 
some advantages in the role of physiological immune systems in prokaryote. There is 
an arms race between bacteria and phages. For phages, alteration of the PAM is one of 
the strategies to avoid the threat of CRISPR-Cas systems. There is a possibility that the 
tolerant PAM recognition may be valuable to defend the host cells form the phages 
with altered PAM. 
 
Recently, AsCpf1 has been engineered to recognize altered PAM sequences, using a 
structure-guided mutation screen (Gao et al., 2017), and the crystal structures of the 
AsCpf1 variants revealed their altered PAM recognition mechanisms (Nishimasu et al., 
2017). Thus, the present findings advance our mechanistic understanding of the 
CRISPR-Cpf1 family nucleases, and will facilitate the engineering of Cpf1, including 
the development of variants with altered PAM specificities. 
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Chapter 5: General discussion 
 
5.1 Conservations of the overall structure in Cpf1 family 
In this study, we described the conservation of the bilobed structures among the Cpf1 
family members by the structural comparisons between the ternary complexes of 
AsCpf1 and LbCpf1. Recently, the crystal structure of FnCpf1–crRNA binary complex 
was reported (Swarts et al., 2017). The amino acid sequence similarities between 
LbCpf1 and FnCpf1 are 40%, and the structural comparison of these binary complexes 
also reveals the structural similarities (Figures 5-1A and 5-1B). This observation 
supports the structural conservations among the Cpf1 family members, suggesting the 
conservations of the conformational changes accompanying the target DNA 
recognitions. 
 
5.2 Structural insights into the target DNA cleavage mechanism of 
Cpf1 
Dong et al. reported the crystal structure of LbCpf1–crRNA binary complex in 2.4 Å 
resolutions and the electron microscopy structure of apo-LbCpf1 and the binary 
complex, and Swarts et al. reported the crystal structures of FnCpf1–crRNA binary 
complex in 3.3 Å resolutions and FnCpf1–crRNA–target DNA R-loop complex in 2.5 
Å resolutions. The R-loop complex contains a full-length double-stranded target DNA. 
The structural comparisons of these structures provide clues about the conformational 
changes of Cpf1 accompanying the crRNA and target DNA binding, and the target 
DNA cleavage mechanisms. The apo-Cpf1 structure showed by negative staining 
electron microscopy displayed an extended conformation, and the particles suggest the 
structural flexibility of the REC and NUC lobes. Both the crystal structure and the EM 
structure of LbCpf1–crRNA binary complexes display triangle shapes. The structural 
comparisons indicate the conformational changes from the extended shape to the 
triangle shape accompanying with crRNA binding. In the structure of LbCpf1–crRNA 
complex, the seed region of the crRNA is not ordered, whereas in FnCpf1–crRNA 
complex five nucleotides in the seed region are ordered and adopt an A-form-like 
helical conformation. The seed region is solvent exposed, and poised for hybridization 
with target DNA strand. However, the overall structures are identical each other 
 140 
(Figures 5-1A and 5-1B), suggesting the recognition of the 5ʹ′-handle of crRNA, not 
the pre-ordering of the seed region, trigger the conformational change of Cpf1 and a 
formation of a preliminary central channel. After that, the target DNA binding induces 
the structural rearrangements of the Rec1 and Rec2 domains in the REC lobe, leading 
to form the central channel as described before (Figures 5-1C and 5-1D). 
In the R-loop structure of FnCpf1, the unwound target dsDNA forms a PAM-distal 
DNA duplex between the Rec2 and Nuc domains (Figure 5-1E). Compared to the 
Cpf1–crRNA–target DNA complexes, the Nuc domain positioned further from the 
Rec2 domain to accommodate the PAM-distal DNA duplex. While we predicted that 
this R-loop structure mimic the physiological DNA cleaving state, the distance 
between the catalytic site of the RuvC domain and the cleavage site of dsDNA was too 
far. Further conformational changes of Cpf1 are suggested from this structure to cleave 
the target DNA. Cpf1 cleave the dsDNA by single nuclease domain, thus the cleavage 
mechanisms are different from Cas9. The cleaving order of the target and non-target 
DNA strand and the conformational changes accompanying the cleavages remain 
elusive. We predict that the other two intermediate states exist which the RuvC domain 
cleaves the target DNA strand and non-target DNA strand. 
 
Recently, there were technical advances in the single particle analysis by cryo-electron 
microscopy (cryo-EM). Cryo-EM is a powerful tool to determine the structure of 
proteins which are not suitable for crystallization. The structure of SpCas9–sgRNA–
tagret DNA complex containing full dsDNA was determined by cryo-EM, and it reveal 
further conformational changes of the HNH domain compared to the SpCas9 R-loop 
structure (Huai et al., 2017; Jiang et al., 2016a). Previous studies suggest that the 
crystallization of Cpf1–crRNA–target DNA complex containing full dsDNA is 
difficult. When the structure is determined by cryo-EM, there is a possibility that we 
can observe some unexpected conformation of Cpf1 and reveal the cleaving order of 
the target DNA. 
 
5.3 The PAM recognition mechanisms of Cpf1 
The crystal structure of FnCpf1 R-loop structure revealed the PAM recognition 
mechanism of FnCpf1. According to the previous reports, FnCpf1 recognizes TTV 
PAM (Zetsche et al., 2015a). The PAM duplex of FnCpf1 was highly distorted, and 
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surrounded by the Rec1, WED, and PI domains (Figures 5-2A and 5-2B). The minor 
groove of the distorted duplex was narrower than the minor groove of the canonical B 
form dsDNA and the PAM duplex of AsCpf1 and LbCpf1 (Figure 5-2C). The 
dT(−1):dA(−1*) base pair in the PAM duplex does not form base-specific contacts 
with the protein. The O2 of dT(−2*) forms a hydrogen bond with Lys671. dA(−2) also 
forms van der Waals interactions with Pro663, Met668 and Lys671 (Figure 5-3A). The 
5-methyl group of dT(−3*) is in the vicinity of the side-chain methyl group of Thr177, 
whereas the N3 and N7 of dA(−3) form hydrogen bonds with Lys671 and Lys613, 
respectively (Figure 5-3B). The 5-methyl group of dT(−4*) is surrounded by the side 
chains of Thr177, whereas the O4ʹ′ of dA(−4) forms a hydrogen bond with Lys671 
(Figure 5-3C). As observed in AsCpf1 and LbCpf1 complexes, the PAM recognition 
mechanisms are conserved in FnCpf1, which is recognized by the combination of the 
shape readout and the base readout (Figures 5-3D–5-3I). The side chain of Lys671, 
which equivalent to Lys607 of AsCpf1 and Lys595 of LbCpf1, is inserted into the 
narrow minor groove and recognizes the distorted shape of the PAM duplex. Moreover, 
Lys671 and Lys613, which equivalent to Lys548 of AsCpf1 and Lys538 of LbCpf1, 
recognize the bases specifically. 
FnCpf1 recognizes TTV PAM, which is simpler than TTTV PAM recognized by 
AsCpf1. Whereas the PAMs are recognized by FnCpf1 and AsCpf1 in same manners 
and all key residues and interactions are conserved among them (Figures 5-3A–5-3F), 
Thr604 in the WED domain, which equivalent to Thr539 of AsCpf1, positioned slight 
further from the methyl group of dT(−4*) compared to Thr539 (Figures 5-3C and 
5-3F). Thr604 does not interact with dT(−4*), and this position makes space around 
the nucleotide. It eliminates the strong preference for a thymine and enables FnCpf1 to 
accept any nucleotides as this position. Furthermore, whereas dT(−4*) in AsCpf1 
complex tilts to the complementary dA(−4) and form hydrogen bonds with dA(−4) and 
dA(−3), dT(−4*) and dA(−4) form canonical AT base pair in the FnCpf1 ternary 
complex (Figures 5-3C and 5-3F). It contributes the TTV PAM recognition mechanism 
of FnCpf1. LbCpf1 prefers the TTTV PAM. However, it also recognizes the 
C-containing PAM, especially the CTTV PAM as a second PAM. In the LbCpf1 
ternary complex, dT(−4*) and dA(−4) form canonical AT base pair similar to the 
FnCpf1 ternary complex, and Gln529 in the WED domain equivalents to Thr539 of 
AsCpf1 and Thr604 of FnCpf1, forms van del Waals interactions with dT(−4*) (Figure 
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5-3I). When a purine nucleotide exists at the first position of the PAM, the steric 
hindrance is predicted between the nucleotide and Gln529, suggesting limits the 
selectivity of nucleotide for a pyrimidine at the first position of the PAM. These 
comparisons of PAM recognition mechanisms suggest the possibility of further 
engineering of Cpf1. When Gln529 of LbCpf1 is substituted to another amino acid 
residue with unbulky side chain, there is some possibility of changing the PAM 
preference of LbCpf1 from TTTV to TTV. 
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